mesalamine and Recrudescence studies

Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.

Research Excerpts

Excerpt	Relevance	Reference
"We evaluated the efficacy of mesalamine (Asacol) in reducing gastrointestinal symptoms after an acute attack of diverticulitis."	9.17	A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. ( Magowan, S; Quigley, EM; Shanahan, F; Stollman, N, 2013)
"To observe the maintenance effect of polyglycosides of Tripterygium wilfordii (GTW) on remission in postoperative Crohn disease (CD)."	9.14	[Maintenance effect of polyglycosides of Tripterygium wilfordii on remission in postoperative Crohn disease]. ( Ji, ZL; Jiang, XH; Li, JS; Ren, JA; Tao, QS; Wang, XB, 2009)
"We report the case of a patient in whom fever, weight loss and pericarditis developed after 16 years of treatment with sulfasalazine for ulcerative colitis, after increasing the daily dosage from 1 to 3 g."	7.74	Sulfasalazine-induced pericarditis in a patient with ulcerative colitis without recurrence when switching to mesalazine. ( Aslangul, E; Gadhoum, H; Le Jeunne, C; Perrot, S; Romnicianu, S; Szwebel, T, 2007)
"Drug-induced acute pancreatitis (DIAP) is an often-neglected entity where the disorder is the consequence of the toxic effects of various agents applied to treat potentially life-threatening conditions, such as inflammatory bowel disease."	5.56	Recurrent acute pancreatitis induced by 5-ASA and azathioprine in ulcerative colitis. ( Bajor, J; Faluhelyi, N; Hegyi, P; Hegyi, PJ; Németh, BC; Szakács, Z, 2020)
"We evaluated the efficacy of mesalamine (Asacol) in reducing gastrointestinal symptoms after an acute attack of diverticulitis."	5.17	A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. ( Magowan, S; Quigley, EM; Shanahan, F; Stollman, N, 2013)
"To observe the maintenance effect of polyglycosides of Tripterygium wilfordii (GTW) on remission in postoperative Crohn disease (CD)."	5.14	[Maintenance effect of polyglycosides of Tripterygium wilfordii on remission in postoperative Crohn disease]. ( Ji, ZL; Jiang, XH; Li, JS; Ren, JA; Tao, QS; Wang, XB, 2009)
"We report the case of a patient in whom fever, weight loss and pericarditis developed after 16 years of treatment with sulfasalazine for ulcerative colitis, after increasing the daily dosage from 1 to 3 g."	3.74	Sulfasalazine-induced pericarditis in a patient with ulcerative colitis without recurrence when switching to mesalazine. ( Aslangul, E; Gadhoum, H; Le Jeunne, C; Perrot, S; Romnicianu, S; Szwebel, T, 2007)
"Acute pancreatitis is a known, although rare, complication of mesalamine treatment."	3.69	Acute pancreatitis after long-term 5-aminosalicylic acid therapy. ( Fernández, J; Feu, F; Navarro, S; Panés, J; Sala, M; Terés, J, 1997)
"Lichen planus is a recognized complication of sulfasalazine therapy."	3.68	Lichen planus and mesalazine. ( Alstead, EM; Farthing, MJ; Wilson, AG, 1991)
"The recurrence of Crohn's Disease after ileo-colonic resection is a crucial issue."	2.94	Azathioprine for prevention of clinical recurrence in Crohn's disease patients with severe endoscopic recurrence: an IG-IBD randomized double-blind trial. ( Angelucci, E; Annese, V; Aratari, A; Biancone, L; Bossa, F; Cappello, M; Castiglione, F; Cottone, M; Di Mitri, R; Giunta, M; Kohn, A; Macaluso, FS; Mocciaro, F; Onali, S; Orlando, A; Papi, C; Renna, S; Rispo, A; Scimeca, D; Scribano, ML; Testa, A; Ventimiglia, M, 2020)
"In SAG-37, the proportion of recurrence-free patients during 48 weeks was 67."	2.84	Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence. ( Banai, J; Björck, S; Bunganic, I; Curtin, A; Derova, J; Diez Alonso, MM; Dilger, K; Dorofeyev, AE; Eisenbach, T; Ferreira, N; Greinwald, R; Kardalinos, V; Kondrackiene, J; Kruis, W; Lukas, M; Mäkelä, J; Mohrbacher, R; Pokrotnieks, J; Safadi, R; Spiller, R; Talley, NJ; Tuculanu, D; Tulassay, Z; Vich, T; Zakko, SF, 2017)
"Ulcerative proctitis is a common and often highly symptomatic form of inflammatory bowel disease."	2.82	Efficacy of Pharmacological Agents for Ulcerative Proctitis: A Systematic Literature Review. ( Caron, B; Danese, S; Hart, A; Panaccione, R; Peyrin-Biroulet, L; Sandborn, WJ; Schreiber, S; Solitano, V, 2022)
"Mesalazine is used as maintenance therapy in ulcerative colitis but the optimal dosage is still controversial."	2.80	A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis. ( Avallone, EV; Cassieri, C; Cocco, A; Crispino, P; De Nitto, D; Marcheggiano, A; Occhigrossi, G; Paoluzi, P; Pica, R; Zippi, M, 2015)
"A 1-year substudy was conducted alongside a trial that compared 2 different dosing regimens (once daily versus three times daily) of mesalazine for patients in remission with ulcerative colitis."	2.79	Electronic monitoring of medication adherence in a 1-year clinical study of 2 dosing regimens of mesalazine for adults in remission with ulcerative colitis. ( Farewell, D; Gillespie, D; Hawthorne, AB; Hood, K; Probert, C; Stenson, R, 2014)
"The incidence of endoscopic recurrence (ER) in Crohn's disease following curative resection is up to 75% at 1 year."	2.79	Early post-operative endoscopic recurrence in Crohn's disease patients: data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. ( Angelucci, E; Annese, V; Aratari, A; Biancone, L; Bossa, F; Cappello, M; Castiglione, F; Cottone, M; D'Incà, R; Fries, W; Gionchetti, P; Kohn, A; Lia Scribano, M; Martinato, M; Mocciaro, F; Onali, S; Orlando, A; Papi, C; Renna, S; Rispo, A; Rizzello, F; Scimeca, D; Tambasco, R; Testa, A; Vernia, P, 2014)
"Among patients with quiescent ulcerative colitis (UC), lower fecal concentrations of calprotectin are associated with lower rates of relapse."	2.79	Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. ( Aberra, FN; Brensinger, C; Cross, R; Gilroy, E; Hardi, R; Lewis, JD; Liakos, S; McCabe, R; Nessel, L; Osterman, MT; Shafran, I; Wolf, D, 2014)
"Japanese ulcerative colitis (UC) patients receiving acute induction therapy with 4."	2.79	Efficacy of long-term 4.0 g/day mesalazine (Pentasa) for maintenance therapy in ulcerative colitis. ( Akazawa, Y; Ichikawa, T; Isomoto, H; Makiyama, K; Matsumura, M; Nakao, K; Nishiyama, H; Ohba, K; Ohnita, K; Takeshima, F; Yamaguchi, N; Yamakawa, M; Yamao, T, 2014)
"At two years, 1/6 patient had clinical recurrence and 1/6 patient had endoscopic and clinical recurrence."	2.79	Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. ( Baldissarro, I; Bodini, G; de Cassan, C; Dulbecco, P; Fazio, V; Giambruno, E; Peyrin-Biroulet, L; Savarino, E; Savarino, V, 2014)
"Patients with subocclusive Crohn's disease (CD) who received azathioprine (AZA) therapy had lower re-hospitalization rates due to all causes and for surgical management of CD compared to those treated with mesalazine during a 3-year period."	2.79	Azathioprine is more effective than mesalazine at preventing recurrent bowel obstruction in patients with ileocecal Crohn's disease. ( Castro, AC; Chebli, JM; Chebli, LA; da Rocha Ribeiro, TC; de Lima Pace, FH; de Oliveira Zanini, KA; de Souza, GS; do Valle Pinheiro, B; Furtado, MC; Gaburri, PD; Machado de Oliveira, J; Pinto, AL; Ribeiro, LC; Vidigal, FM; Zanini, A, 2014)
"Clinical and endoscopic recurrences were less common in the GTW group (n = 4) versus the 5-ASA group (n = 9)."	2.78	Prevention of postoperative recurrence of Crohn's disease: Tripterygium wilfordii polyglycoside versus mesalazine. ( Fan, C; Li, J; Liao, N; Liu, S; Ren, H; Ren, J; Wang, G; Wu, X; Zhao, Y, 2013)
"Recurrence of diverticulitis is frequent within 5 years from the uncomplicated first attack, and its prophylaxis is still unclear."	2.78	Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double-blind placebo-controlled study of 24-month duration. ( Bargiggia, S; Bortoli, A; Casella, G; De Pretis, G; Ferrari, A; Germanà, B; Giacosa, A; Miori, G; Parente, F; Prada, A, 2013)
"The primary endpoint was clinical recurrence at Month 6."	2.77	Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis. ( Barrett, K; Dolin, B; Jamal, MM; Kane, S; Katz, S; Palmen, M; Safdi, M; Solomon, D, 2012)
"Ninety-five eligible patients with Crohn's disease activity index ≤150 were randomly assigned to: 6-mercaptopurine (0."	2.77	Nutritional therapy versus 6-mercaptopurine as maintenance therapy in patients with Crohn's disease. ( Abe, J; Arai, H; Arai, O; Hanai, H; Iida, T; Ikeya, K; Maruyama, Y; Nakamura, K; Nakamura, T; Sugimoto, K; Takeuchi, K; Tanaka, T; Watanabe, F, 2012)
"The decrease in ulcerative colitis disease activity index (UCDAI) scores of 50% or more was higher in the VSL#3 group than in the placebo group (63."	2.75	Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. ( Annese, V; Brandimarte, G; D'Amico, T; Danese, S; Di Giulio, E; Di Rosa, S; Elisei, W; Forti, G; Gasbarrini, A; Giglio, A; Giorgetti, GM; Hassan, C; Imeneo, M; Larussa, T; Luzza, F; Modeo, ME; Morini, S; Papa, A; Pistoia, MA; Rodino', S; Sacca', N; Sebkova, L; Tursi, A, 2010)
"Relapse was defined as SDAI rectal bleeding score ≥1 and a mucosal appearance score ≥2, a UC flare, or initiation of medication to treat a UC flare."	2.75	Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial. ( Bortey, E; Forbes, WP; Gordon, GL; Lichtenstein, GR; Merchant, K; Murthy, U; Pruitt, R; Sedghi, S; Shaw, A; Zakko, S, 2010)
"Patients with Crohn's disease who underwent an ileocolic resection were randomized to side-to-side anastomosis or end-to-end anastomosis."	2.74	Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. ( McKenzie, M; McLeod, RS; Parkes, R; Ross, S; Wolff, BG, 2009)
"2 g/tablet) is a 5-aminosalicylic acid formulation, designed for once-daily dosing in the treatment of ulcerative colitis."	2.74	Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. ( Ardia, A; Bellinvia, S; Campieri, M; Caprilli, R; Cottone, M; Kohn, A; Pallone, F; Prantera, C; Savarino, V; Sturniolo, GC; Vecchi, M, 2009)
"Six patients (15%) showed recurrence of symptoms: 1 in group A (5."	2.73	Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. ( Brandimarte, G; Elisei, W; Giorgetti, GM; Tursi, A, 2007)
" This study evaluated the safety and efficacy of MMX mesalazine dosed once or twice daily as maintenance therapy in patients with ulcerative colitis."	2.73	Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. ( Barrett, K; Joseph, R; Kamm, MA; Lees, K; Lichtenstein, GR; Sandborn, WJ; Schreiber, S, 2008)
" No clear relationship, however, has been shown between dosage and response."	2.71	Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial. ( Annese, V; Cammà, C; Caprilli, R; Castiglione, F; Corrao, G; Cottone, M; Latella, G; Papi, C; Sturniolo, G; Tonelli, F; Viscido, A, 2003)
"To assess the feasibility, safety and efficacy of patient-led dosing using balsalazide in the long-term treatment of ulcerative colitis."	2.71	Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study. ( Gibson, JA; Green, JR; Kerr, GD; Swan, CH; Swarbrick, ET; Thornton, PC, 2004)
"The scheduled oral + topical 5-ASA treatment, at the lowest cumulative topical dosage tested over the longest known observation period, is efficacious in improving clinical outcome and decreasing overall costs in UC patients."	2.71	Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis. ( Cermesoni, L; Cesana, BM; Piodi, LP; Ulivieri, FM, 2004)
"The cumulative recurrence rate in the GBF group with steroid tapering treatment was significantly lower compared with the value in the control group."	2.71	Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. ( Andoh, A; Araki, Y; Bamba, T; Fujiyama, Y; Fukuda, M; Hanai, H; Kanauchi, O; Kojima, A; Mitsuyama, K; Sata, M; Takayuki, I; Takeuchi, K; Toyonaga, A, 2004)
"The continuous use of topical mesalazine associated with a high oral dosage significantly improves the clinical course of ulcerative colitis patients at high risk of relapse."	2.71	Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis. ( Caprilli, R; Chiaramonte, M; Corrao, G; Frieri, G; Galletti, B; Latella, G; Palumbo, G; Pimpo, M, 2005)
" However, the optimal dosage remains to be defined."	2.71	Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. ( Consolazio, A; Crispino, P; Iacopini, F; Marcheggiano, A; Paoluzi, OA; Paoluzi, P; Pica, R; Rivera, M, 2005)
"Preliminary data have shown that delayed release oral mesalamine (Asacol) dosed at 4."	2.71	Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. ( Ajayi, F; Hanauer, SB; Katz, S; Kornbluth, A; Regalli, G; Safdi, M; Sandborn, WJ; Smith-Hall, N; Woogen, S; Yeh, C, 2005)
"Ulcerative colitis is managed mainly in secondary care by regular outpatient reviews done by specialist clinicians."	2.70	Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial. ( Roberts, C; Robinson, A; Thompson, DG; Wilkin, D, 2001)
" The dose-response relationship was statistically significant (p = 0."	2.69	Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group. ( Bianchi Porro, G; Campieri, M; d'Albasio, G; Miglioli, M; Paoluzi, P; Pera, A; Prantera, C; Sturniolo, GC, 1998)
"Ulcerative colitis has been suggested to be caused by infection and there is circumstantial evidence linking Escherichia coli with the condition."	2.69	Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. ( Axon, AT; Chalmers, DM; Hawkey, PM; Rembacken, BJ; Snelling, AM, 1999)
"Twenty patients with ulcerative colitis, intolerant or allergic to 5-ASA, have been treated with a new probiotic preparation (VSL#3, CSL, Milan, Italy) containing 5x10(11) cells/g of 3 strains of bifidobacteria, 4 strains of lactobacilli and 1 strain of Streptococcus salivarius ssp."	2.69	Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. ( Brigidi, P; Campieri, M; Gionchetti, P; Johansson, R; Matteuzzi, D; Rizzello, F; Venturi, A; Zucconi, E, 1999)
"Risk factors for recurrence were prospectively defined to be analyzed in a stepwise proportional hazards model."	2.69	Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. ( Bauer, P; Fleig, WE; Genser, D; Gross, V; Hoffmann, R; Lochs, H; Mayer, M; Mortensen, PB; Nesje, LB; Petritsch, W; Plauth, M; Raithel, M; Staun, M, 2000)
"Thirty-two patients with Crohn's disease in clinical remission (CDAI < 150) were randomly treated for six months with either mesalamine 1 g three times a day or mesalamine 1 g two times a day plus a preparation of Saccharomyces boulardii 1 g daily."	2.69	Saccharomyces boulardii in maintenance treatment of Crohn's disease. ( Guslandi, M; Mezzi, G; Sorghi, M; Testoni, PA, 2000)
"Endoscopic recurrence occurred in 5/10 patients who received placebo and 6/11 patients who received mesalazine."	2.68	Remaining small bowel endoscopic lesions at surgery have no influence on early anastomotic recurrences in Crohn's disease. ( Colombel, JF; Cortot, A; Desreumaux, P; Gambiez, L; Klein, O; Lescut, D; Quandalle, P, 1995)
"Recurrence of Crohn's disease frequently occurs after surgery."	2.68	Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. ( Andrews, DF; Blair, JE; Cangemi, JR; Carryer, PW; Cohen, Z; Cullen, JB; McLeod, RS; O'Rourke, K; Steinhart, AH; Wolff, BG, 1995)
"Recurrence of lesions of Crohn's disease of the ileum within 1 year after so-called curative resection was well documented by endoscopy in 73%-93% of cases."	2.68	Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. ( Ardizzone, S; Brignola, C; Cottone, M; D'Albasio, G; D'Arienzo, A; De Franchis, R; Pennestri, D; Pera, A; Scribano, ML, 1995)
"The activity and localization of Crohn's disease were defined according to the "Crohn's disease activity index" (CDAI) and the "laboratory index" (LI), as well as by endoscopy and (or) radiology."	2.68	[5-Aminosalicylic acid in the prevention of recurrences of Crohn's disease]. ( Bresci, G; Del Corso, L; Moruzzo, D; Norpoth, M; Pentimone, F; Romanelli, AM, 1995)
"Prognostic factors for postoperative recurrence of Crohn's disease (CD) have been widely investigated but not yet clearly identified."	2.68	Prognostic factors for postoperative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC) ( Caprilli, R; Corrao, G; Taddei, G; Tonelli, F; Torchio, P; Viscido, A, 1996)
"One hundred fifty patients with active Crohn's disease were administered oral prednisolone (1 mg."	2.68	Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. ( Belaïche, J; Cadiot, G; Colombel, JF; Costil, V; Danne, O; Dapoigny, M; Duclos, B; Dupas, JL; Galmiche, JP; Gendre, JP; Lamouliatte, H; Mary, JY; Modigliani, R; Soulé, JC; Veyrac, M, 1996)
"Endoscopic postoperative recurrences occur early after 'curative' surgery for Crohn's disease."	2.68	Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). ( Belaiche, J; Cortot, A; Daurat, M; Dupas, JL; Faucheron, JL; Florent, C; Gendre, JP; Jacquet, N; Lerebours, E; Malafosse, M; Michot, F; Modigliani, R; Quandale, P; Rothman, N; Sahmound, T; Sarfaty, E; Soulé, JC; Valleur, P, 1996)
"Mesalamine treatment reduced relapse compared with placebo treatment, although conventional statistical significance was not achieved."	2.68	A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. ( Bailey, RJ; Dallaire, C; Fedorak, RN; Lariviere, L; Martin, F; Poleski, M; Rossman, R; Saibil, F; Sutherland, LR, 1997)
"4-Aminosalicylic acid (4-ASA) has been suggested as an effective treatment for both active and quiescent ulcerative colitis."	2.67	Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis. ( Howaldt, S; Raedler, A; Schreiber, S, 1994)
"The cumulative proportion of recurrence at 6, 12 and 24 months was significantly lower in the mesalazine group than in untreated group (P = 0."	2.67	Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). ( Andreoli, A; Assuero Lanfranchi, G; Caprilli, R; Capurso, L; Corrao, G; D'Albasio, G; Gioieni, A; Paladini, I; Pallone, F; Ponti, V, 1994)
"Thirty-eight patients with distal ulcerative colitis (n = 17) or ulcerative proctitis (n = 21) in clinical, endoscopic, and histologic remission were randomly assigned to receive either oral mesalazine (0."	2.67	Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. ( Hatzis, A; Mantzaris, GJ; Petraki, K; Spiliadi, C; Triantaphyllou, G, 1994)
"Olsalazine was clearly superior to mesalazine in prevention of relapses in ulcerative colitis, especially in patients with left-sided disease."	2.67	Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. ( Bergin, CF; Courtney, MG; Keeling, PW; Nunes, DP; O'Driscoll, M; Trimble, V; Weir, DG, 1992)
"Treatment of Crohn's disease (CD) in clinical remission is still a debated issue."	2.67	Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. ( Barbara, L; Basso, O; Belluzzi, A; Brignola, C; Campieri, M; Gionchetti, P; Iannone, P; Miglioli, M; Pasquali, S, 1992)
"The patients had Crohn's disease for an average of 5 years, with their disease clinically inactive for at least 1 month prior to entry into the study, and for an average of over 12 months previously."	2.67	Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group. ( , 1990)
"Microscopic colitis is a common cause of chronic watery diarrhea with a great impact on patient quality of life."	2.66	Treatment of microscopic colitis: the role of budesonide and new alternatives for refractory patients. ( Casanova, MJ; Gisbert, JP; Rojo, E, 2020)
"Consequently, new alternatives for the treatment of ulcerative colitis are constantly being sought."	2.66	Probiotics for maintenance of remission in ulcerative colitis. ( Akobeng, AK; Baines, PA; Gordon, M; Iheozor-Ejiofor, Z; Kaur, L; Sinopoulou, V, 2020)
"About half of patients with Crohn's disease (CD) require surgery within 10 years of diagnosis."	2.66	Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease. ( Bravo-Soto, GA; Candia, R; Hernandez, C; Monrroy, H; Nguyen, GC, 2020)
"To assess the efficacy, dose-responsiveness, and safety of oral 5-ASA compared to placebo, SASP, or 5-ASA comparators for maintenance of remission in quiescent UC and to compare the efficacy and safety of once-daily dosing of oral 5-ASA with conventional (two or three times daily) dosing regimens."	2.66	Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. ( Feagan, BG; MacDonald, JK; Murray, A; Nguyen, TM; Parker, CE, 2020)
"Sulfasalazine is an effective drug for maintaining remission in ulcerative colitis, but its use may be precluded by side effects."	2.66	Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine. ( Greenberg, GR; Habal, FM, 1988)
" Long-term use of olsalazine in controlled trials may be considered safe, even in high doses."	2.66	Colonic prostaglandin E2 levels and olsalazine metabolism in relapsing ulcerative colitis: implications for controlled trials in the long term. ( Bukhave, K; Lauritsen, K; Laursen, LS; Rask-Madsen, J, 1988)
"Secondary outcomes included endoscopic recurrence, radiologic and surgical relapse, adverse events, serious adverse events and withdrawal due to adverse events."	2.61	Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. ( Akobeng, AK; Gjuladin-Hellon, T; Gordon, M; Iheozor-Ejiofor, Z, 2019)
"Mesalazine does not prevent the recurrence of diverticulitis in patients with SUDD."	2.58	Effect of mesalazine on recurrence of diverticulitis in patients with symptomatic uncomplicated diverticular disease: a meta-analysis with trial sequential analysis of randomized controlled trials. ( Ali, B; Hajibandeh, S; Khan, RMA, 2018)
"Here, we report a case of recurrent acute pancreatitis secondary to 5-aminosalicylic acid, with positive unintentional rechallenge."	2.58	5-ASA induces mild acute pancreatitis. Case report and review of the literature. ( Hegyi, P; Meczker, Á; Mikó, A, 2018)
"Patients with ulcerative colitis (UC) who achieve remission with corticosteroids often relapse after tapering or discontinuation; alternative treatments limiting steroid exposure and UC relapse would be beneficial."	2.53	Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission. ( Barrett, AC; Bortey, E; Forbes, WP; Gordon, GL; Lichtenstein, GR; Murthy, U; Paterson, C; Pruitt, R; Sedghi, S; Zakko, S, 2016)
" A secondary objective was to compare the efficacy and safety of once daily dosing of oral 5-ASA with conventional (two or three times daily) dosing regimens."	2.53	Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. ( Feagan, BG; MacDonald, JK; Parker, CE; Wang, Y, 2016)
"Ulcerative colitis is an immunologic disorder of the intestine which involves the mucosa and sometimes the submucosa."	2.53	[Ulcerative colitis]. ( Biedermann, L; D'cunja, J; Roose, L, 2016)
"Efficacy in treating postoperative Crohn's disease recurrence will require further investigation."	2.52	Prevention and treatment of postoperative Crohn's disease recurrence with anti-TNF therapy: a meta-analysis of controlled trials. ( Carla-Moreau, A; Genin, C; Paul, S; Peyrin-Biroulet, L; Roblin, X, 2015)
"The incidence of diverticulosis and diverticular disease of the colon, including diverticulitis, is increasing worldwide, and becoming a significant burden on national health systems."	2.52	Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon. ( Danese, S; Papa, A; Tursi, A, 2015)
"Conservative measures in prevention recurrence are dietary advises and medical therapies, including probiotics and 5-aminosalicylic acid."	2.48	Systematic review of medical therapy to prevent recurrent diverticulitis. ( Boermeester, MA; Daniels, L; Unlü, C; Vrouenraets, BC, 2012)
" A secondary objective was to compare the efficacy and safety of once daily dosing of oral 5-ASA with conventional (two or three times daily) dosing regimens."	2.48	Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. ( Feagan, BG; Macdonald, JK, 2012)
"Curcumin was administered orally in a dose of 2 g/day for six months."	2.48	Curcumin for maintenance of remission in ulcerative colitis. ( Ahuja, V; Kumar, A; Kumar, S; Moss, AC; Sankar, MJ, 2012)
"Crohn's disease is a chronic, progressive disabling condition ultimately leading to stricturing and/or penetrating complications."	2.46	[Postoperative recurrence of Crohn's disease, and its prevention]. ( Lakatos, L; Lakatos, PL, 2010)
" Consequently, new guidelines for the management of distal colitis have focussed more on rectal delivery and on optimizing 5-ASA dosage than previously."	2.44	Management of distal ulcerative colitis: frequently asked questions analysis. ( Gearry, RB; Gibson, PR; Irving, PM; James, SL, 2008)
" Nonadherence may be affected by such factors as complicated dosing regimens, forgetfulness, male sex, and treatment delivery methods."	2.44	Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitis. ( Lichtenstein, GR; Rubin, DT; Sabesin, SM; Velayos, FS; Vitat, P, 2008)
" This review examines the prevalence and impact of non-adherence to 5-aminosalicylic acid therapy among patients with ulcerative colitis, as well as drug delivery strategies that may enhance dosing regimens to improve patient acceptability, adherence and long-term clinical outcomes."	2.43	Systematic review: adherence issues in the treatment of ulcerative colitis. ( Kane, SV, 2006)
" Similarly, when 5-aminosalicylic acids are used to induce remission, continuing the induction dosage for an extra 4 weeks prolongs remission and reduces the frequency of relapse."	2.43	Review article: maintenance therapy in patients with ulcerative colitis. ( Keshav, S; Orchard, T; Probert, CS, 2006)
"Ulcerative colitis is a chronic inflammatory bowel disease."	2.42	[Management of ulcerative colitis]. ( Kullak-Ublick, GA; Rammert, Ch, 2003)
"Ulcerative colitis is characterized by chronic inflammation of the colon."	2.42	Ulcerative colitis: conservative management and long-term effects. ( Fölsch, UR; Kühbacher, T; Schreiber, S, 2004)
"It describes the treatment of ulcerative colitis according to the different groups of patients and the degree of activity."	2.41	[Conservative therapy of inflammatory bowel diseases]. ( Nagy, F, 2002)
" Metronidazole and 6-mercaptopurine or azathioprine also seem to be of benefit in postoperative prophylaxis of disease recurrence, but additional controlled studies are required to define better the efficacy and dose-response of these agents."	2.41	Medical therapy to reduce postoperative Crohn's disease recurrence. ( Achkar, JP; Hanauer, SB, 2000)
" Oral controlled-release budesonide has demonstrated comparable efficacy to prednisolone with less risk for adverse effects, although many questions remain regarding the long-term use of this agent."	2.41	Conventional treatment of Crohn's disease: objectives and outcomes. ( Rutgeerts, PJ, 2001)
"Often, relapse is related to the failure of maintenance therapy."	2.40	Factors influencing the relapse of patients with inflammatory bowel disease. ( Miner, PB, 1997)
"Crohn's recurrence is the appearance of objective signs defined radiologically, endoscopically or pathologically of Crohn's disease in the bowel of a patient who has previously had a resection of all macroscopically diseased tissue."	2.40	[Drug prevention of Crohn disease recurrence in the neo-terminal ileum after ileocolic resection]. ( Rutgeerts, P; Vermeire, S, 1998)
"The recurrence rate of Crohn's disease after surgery is very high."	2.40	[Therapy of Crohn disease in internal medicine: postoperative recurrence and fistulas]. ( Blum, HE; Volk-Zeiher, BA, 1998)
"In view of a high recurrence rate of Crohn's disease after surgical resection prophylaxis is desirable."	2.39	[Crohn disease: prevention and drug therapy]. ( Andus, T; Gross, V; Schölmerich, J, 1995)
"While surgery for Crohn's disease is usually effective initially, its long-term benefits may be diminished by the risk of recurrent disease."	2.39	Is it possible to prevent recurrent Crohn's disease with medical or surgical interventions? ( Mcleod, RS, 1996)
"The final message is that in active Crohn's disease surgery should not be excessively delayed."	2.39	[Postoperative recurrence in Crohn's disease]. ( Caprilli, R; Taddei, G; Viscido, A, 1995)
"Crohn's disease is a chronic inflammatory intestinal disorder characterized in most patients by repeated episodes of diminished and exacerbated symptoms."	2.38	Maintenance of symptomatic remission in patients with Crohn's disease. ( Stark, ME; Tremaine, WJ, 1993)
"Mesalamine use was associated with fewer relapses in UC/IBDU patients (aHR, 0."	1.91	Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease. ( Akol-Simsek, D; Colombel, JF; de Koning, DB; Fidder, HH; Goetgebuer, R; Hoentjen, F; Horjus-Talabur Horje, CS; Jansen, JM; Jharap, B; Lutgens, MWMD; Mahmmod, N; Mahmoud, R; Mares, W; Minderhoud, I; Oldenburg, B; Römkens, TEH; Savelkoul, EHJ; van Boeckel, PGA; van Schaik, FDM; van Tuyl, SAC; Witteman, BJM, 2023)
"Cumulative incidences of recurrence were estimated with a Bayesian multivariable proportional hazards model."	1.72	Indications, Postoperative Management, and Long-term Prognosis of Crohn's Disease After Ileocecal Resection: A Multicenter Study Comparing the East and West. ( Arkenbosch, JHC; Beelen, EMJ; Bodelier, AGL; de Boer, NKH; de Vries, AC; Dijkstra, G; Erler, NS; Ho, JCL; Hoentjen, F; Mak, JWY; Ng, SC; Romberg-Camps, M; Stassen, LPS; van der Meulen, AE; van der Woude, CJ; van Ruler, O; West, R, 2022)
"The difference in 6 months recurrence rates of subjects receiving or not receiving mesalazine was the primary outcome measure."	1.72	The role of mesalazine co-treatment in the prevention of recurrence in subjects with subclinical inflammatory bowel disease and perianal fistula who are scheduled for surgical intervention. ( Akturk, R; Serinsöz, S, 2022)
"The long-term outcomes of Ulcerative colitis (UC) after discontinuation of biological therapy are largely unknown."	1.72	Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10 year follow up study. ( Beilfuss, J; Florholmen, J; Goll, R; Gundersen, M; Johnsen, KM; Kileng, H; Moe, ØK; Sørbye, SW, 2022)
"Histologic remission in ulcerative colitis (UC) patients may be associated with positive outcomes."	1.56	Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission. ( Al-Saedi, M; Alshahrani, AA; Aruljothy, A; Christensen, B; Fadida, M; Marshall, JK; Narula, N; Rubin, DT, 2020)
"Drug-induced acute pancreatitis (DIAP) is an often-neglected entity where the disorder is the consequence of the toxic effects of various agents applied to treat potentially life-threatening conditions, such as inflammatory bowel disease."	1.56	Recurrent acute pancreatitis induced by 5-ASA and azathioprine in ulcerative colitis. ( Bajor, J; Faluhelyi, N; Hegyi, P; Hegyi, PJ; Németh, BC; Szakács, Z, 2020)
"Prednisolone treatment successfully induced clinical remission and mucosal healing."	1.51	A case of nivolumab-associated colitis, which relapsed after mucosal healing and was then successfully treated with mesalazine. ( Akemoto, Y; Asari, T; Chinda, D; Fukuda, S; Fukutoku, Y; Hasui, K; Hiraga, H; Kikuchi, H; Mikami, T; Murai, Y; Sakuraba, H; Sawaya, M; Tanaka, M; Tatsuta, T, 2019)
"Observational, cohort study of ulcerative colitis (UC) patients in clinical remission at least 6 months on 5-ASA monotherapy maintenance prescribed by an electronic management program."	1.51	Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system. ( Anton, R; Ballester, MP; Bosca-Watts, MM; Fullana, M; Marti-Aguado, D; Minguez, M; Mora, F; Navarro-Cortes, P; Romero, E; Sanchez, A; Tosca, J, 2019)
"A 35-year-old woman with ulcerative colitis was diagnosed to have acute eosinophilic pneumonia after 29 days of oral mesalazine use and improved after mesalazine and corticosteroid were withdrawn."	1.51	Recurrent Eosinophilic Pneumonia Associated with Mesalazine Suppository in a Patient with Ulcerative Colitis. ( Kang, SB; Lee, J; Park, M; Park, Y, 2019)
"The therapy of the inflammatory bowel diseases is quite complex."	1.48	The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets. ( Astegiano, M; Caviglia, GP; Finocchiaro, F; Pellicano, R; Ribaldone, DG; Saracco, GM; Vernero, M, 2018)
"Efficacy of maintenance therapy in ulcerative colitis (UC) in the remission stage has been reported to depend on release profile or dosing regimen of oral 5-aminosalicylic acid (5-ASA) products used."	1.46	Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study. ( Hanai, H; Hibi, T; Kochi, S; Nagahori, M; Nakamura, S; Omuro, S; Watanabe, M; Yamamoto, T, 2017)
"Most Crohn's disease (CD) patients develop endoscopic recurrence within one year of intestinal resection."	1.46	Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. ( Allocca, M; Armuzzi, A; Bonovas, S; Danese, S; Fiorino, G; Furfaro, F; Landi, R; Papa, A; Peyrin-Biroulet, L; Spinelli, A, 2017)
"Endoscopic recurrence (ER) was defined using the Rutgeerts score (RS), and clinical recurrence (CR) was defined as symptoms of CD with endoscopic or radiologic evidence of neo-terminal ileal disease."	1.46	Rates and Predictors of Endoscopic and Clinical Recurrence After Primary Ileocolic Resection for Crohn's Disease. ( Bellolio, F; Cohen, Z; Fortinsky, KJ; Greenberg, G; Kevans, D; Macrae, H; McLeod, R; Milgrom, R; Qiang, J; Silverberg, MS; Steinhart, H; Stempak, J; Xu, W, 2017)
"In both Crohn's disease and ulcerative colitis patients in deep remission, the incidence rate of relapse was 19% per patient-year."	1.46	Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. ( Aicart, M; Alcaín, G; Almela, P; Arguelles-Arias, F; Arias-Rivera, ML; Barreiro-de Acosta, M; Barrio, J; Beltrán, B; Benítez, JM; Bermejo, F; Botella, B; Bujanda, L; Busquets, D; Calvet, X; Casanova, MJ; Castaño-Milla, C; Castro, E; Castro, L; Ceballos, D; Chaparro, M; Cortés, X; Domènech, E; Domínguez, M; Domínguez-Antonaya, M; Dueñas, C; Esteve, M; Fernández-Salazar, L; García-Herola, A; García-López, S; García-Planella, E; García-Sánchez, V; García-Sepulcre, MF; Garrido, E; Gisbert, JP; Gómez-García, M; Gomollón, F; González-Lama, Y; Guardiola, J; Gutiérrez, A; Hernández-Martínez, A; Hervías, D; Hinojosa, J; Huguet, JM; Jauregui-Amezaga, A; Khorrami, S; Leo, E; Llaó, J; Lorente-Poyatos, R; Mañosa, M; Marín-Jiménez, I; Marrero, JM; Martín-Arranz, M; Martinez-Montiel, MP; Menacho, M; Merino, O; Monfort, D; Moraleja, I; Muñoz, C; Muñoz, F; Nantes, O; Navarro-Llavat, M; Novella, MT; Opio, V; Pajares, R; Pérez-Calle, JL; Pérez-Martínez, I; Pineda, JR; Ponferrada, A; Ramírez-de la Piscina, P; Ramos, L; Robles-Alonso, V; Rodríguez, C; Rodríguez, GE; Rodríguez-Pérez, A; Rojas-Feria, M; Roncedo, O; Sánchez-Torres, A; Sicilia, B; Taxonera, C; Tosca, J; Van Domselaar, M; Vázquez, JM; Vega-López, AB, 2017)
"Twenty-two patients with ulcerative colitis in clinical relapse and 7 control subjects referred for colonoscopy were enrolled."	1.43	Confocal laser endomicroscopy in ulcerative colitis: a longitudinal study of endomicroscopic changes and response to medical therapy (with videos). ( Brynskov, J; Ciocalteu, A; Hendel, J; Karstensen, JG; Klausen, P; Klausen, TW; Riis, LB; Săftoiu, A; Vilmann, P, 2016)
"Recurrent Clostridium difficile infection (rCDI) contributes to a significant burden of disease in patients with inflammatory bowel disease (IBD)."	1.43	Recurrence of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease: The RECIDIVISM Study. ( Bahreini, Z; McGeer, A; Nguyen, GC; Razik, R; Rumman, A, 2016)
"Disease relapse was measured at each visit."	1.43	The Effects of Active IBD During Pregnancy in the Era of Novel IBD Therapies. ( de Lima-Karagiannis, A; van der Woude, CJ; Zelinkova-Detkova, Z, 2016)
"The medical treatment of ulcerative colitis (UC) has seen a change towards a more active attitude during recent years, including both the use of more traditional drugs as well as new biological substances."	1.43	Low colectomy rate five years after diagnosis of ulcerative colitis. Results from a prospective population-based cohort in Sweden (ICURE) diagnosed during 2005-2009. ( Holmström, T; Karlbom, U; Rönnblom, A; Sjöberg, D; Tanghöj, H; Thörn, M, 2016)
"Colonic diverticulosis is an increasingly common condition in Western industrialized countries."	1.43	Treatment of Diverticular Disease With Aminosalicylates: The Evidence. ( Barbara, G; Barbaro, MR; Bellacosa, L; Cremon, C; Stanghellini, V, 2016)
"Prophylactic treatment of postoperative Crohn's disease (CD) plays a critical role in maintaining clinical remission."	1.43	Trends in Pharmacologic Interventions for Preventing Recurrence of Crohn's Disease After Ileocolonic Surgery. ( Grand, RJ; Mandl, KD; Ong, MS, 2016)
"The management of patients with ulcerative colitis who are dependent on corticosteroid for control of symptoms, or refractory to corticosteroids or standard immunosuppressive therapy, is challenging."	1.42	New Zealand Society of Gastroenterology Guidelines for the Management of Refractory Ulcerative Colitis. ( Day, AS; Eliadou, E; Gearry, RB; Inns, SJ; Rowbotham, DS; Schultz, M; Thompson-Fawcett, MW; Walmsley, R, 2015)
"For the prevention of postoperative recurrence, patients were stratified to receive 5-aminosalicylic acid, azathioprine or daikenchuto, and their effects on preventing reoperation at 3 years were evaluated."	1.40	Daikenchuto, a traditional Japanese herbal medicine, for the maintenance of surgically induced remission in patients with Crohn's disease: a retrospective analysis of 258 patients. ( Kanazawa, A; Kawaguchi, T; Okamoto, K; Sahara, R; Sako, M; Tadami, T; Takazoe, M; Yamana, T; Yoshimura, N, 2014)
"Thiopurines prevent Crohn's disease (CD) endoscopic recurrence (ER) at least in 50% of patients 1 year after surgery."	1.40	Addition of mesalazine for subclinical post-surgical endoscopic recurrence of Crohn's disease despite preventive thiopurine therapy: A case-control study. ( Bernal, I; Boix, J; Cabré, E; Domènech, E; Lorenzo-Zúñiga, V; Mañosa, M; Marín, L; Moreno, V; Zabana, Y, 2014)
"It has been recommended that the treatment of active ulcerative colitis (UC) should be continued until complete healing of endoscopic lesions."	1.38	Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. ( Colombo, E; D'Incà, R; Fasoli, R; Gullotta, R; Lombardi, G; Meucci, G; Saibeni, S; Terpin, M; Valpiani, D, 2012)
"Although the early outcomes of ulcerative colitis after a first course of corticosteroids are well known, data on long-term disease evolution in patients responding to a first corticosteroid course are scarce."	1.38	Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids. ( Cabré, E; Domènech, E; Garcia-Planella, E; Gordillo, J; López San Román, A; Mañosa, M; Van Domselaar, M; Zabana, Y, 2012)
"We herein report a patient with erythema induratum/nodular vasculitis (EI/NV) associated with Crohn's disease (CD), which is considered to be a rare type of metastatic CD."	1.38	Erythema induratum (nodular vasculitis) associated with Crohn's disease: a rare type of metastatic Crohn's disease. ( Misago, N; Narisawa, Y, 2012)
"Relapses were treated in the same manner as the first attack in both groups."	1.38	Long-term clinical impact of early introduction of granulocyte and monocyte adsorptive apheresis in new onset, moderately active, extensive ulcerative colitis. ( Matsumoto, K; Umegae, S; Yamamoto, T, 2012)
"A total of 20 IBD (14 Crohn's disease, 6 ulcerative colitis) HIV infected patients and 40 matched control seronegative IBD patients (2 controls per case) were compared regarding relapse of their disease."	1.36	Course of inflammatory bowel disease in patients infected with human immunodeficiency virus. ( Baraboutis, IG; Georgiadis, D; Georgiou, O; Karamanolis, DG; Papastamopoulos, V; Rodias, M; Skoutelis, A; Viazis, N; Vlachogiannakos, J, 2010)
"During the follow-up period, cumulative recurrence rates for intestinal BD were 24."	1.36	Response rates to medical treatments and long-term clinical outcomes of nonsurgical patients with intestinal Behçet disease. ( Cheon, JH; Chung, MJ; Kim, NK; Kim, SU; Kim, TI; Kim, WH; Park, JJ, 2010)
"To describe the long-term prognosis of ulcerative colitis (UC) and to establish whether a correlation exists between the different anatomic locations of the disease and the risk of relapse in a homogeneous cohort of patients with UC in clinical remission, all treated with fixed doses of oral mesalamine from the date of enrollment to the appearance of the first relapse."	1.35	Duration of remission and long-term prognosis according to the extent of disease in patients with ulcerative colitis on continuous mesalamine treatment. ( Bresci, G; Capria, A; Parisi, G, 2008)
"To investigate the occurrence of adverse events and efficacy of azathioprine with or without mesalazine."	1.35	Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease?: an audit of adverse events and outcome. ( Edwards, CM; Probert, CS; Shah, JA, 2008)
" Nonadherence to therapy can be associated with several other factors, including forgetfulness, male sex, complicated dosing regimens, treatment delivery methods (oral vs."	1.34	Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs. ( Boltri, JM; Tindall, WN; Wilhelm, SM, 2007)
"8 g per day of the active 5-aminosalicylate moiety, rather than starting at a lower dosage and increasing if treatment fails."	1.34	Ulcerative colitis: responding to the challenges. ( Achkar, JP, 2007)
"The primary outcome was clinical recurrence of ulcerative colitis."	1.32	Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. ( Aikens, J; Hanauer, S; Huo, D; Kane, S, 2003)
"Data from all patients with Crohn's disease whose diagnosis had been performed before 1st January 1978 were analyzed."	1.32	Crohn's disease over 20 years after diagnosis in a referral population. ( Beaugerie, L; Bouhnik, Y; Cosnes, J; Etienney, I; Gendre, JP; Lémann, M; Matuchansky, C; Modigliani, R; Rambaud, JC, 2004)
"Relapse was defined as an increase in Clinical Activity Index and Endoscopic Index, of more than 6 and 4, respectively."	1.31	Long-term maintenance treatment in ulcerative colitis: a 10-year follow-up. ( Bertoni, M; Bresci, G; Capria, A; Parisi, G, 2002)
"Symptomatic recurrence of diverticulitis occurred in 3 patients in group A, while 13 patients showed recurrence of diverticulitis in group B (p < 0."	1.31	Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. ( Brandimarte, G; Daffinà, R; Tursi, A, 2002)
"Relapse was defined by CD Activity Index > or = 150, CD Endoscopic Index of Severity > or =4, and by an abnormal increase of C-reactive protein, white blood cell count, and erythrocyte sedimentation rate; moreover, if it was confirmed by x-ray and/or endoscopy."	1.31	Does the initial location of Crohn's disease have an influence on the time-to-relapse in patients under maintenance treatment with oral mesalamine? ( Bertoni, M; Bresci, G; Capria, A; Masolino, P; Parisi, G; Scatena, F, 2000)
"Coloscopy demonstrated Crohn's disease of the colon, more marked on the left."	1.31	[Acute pancreatitis--adverse effect of 5-aminosalicylic acid (mesalazine) in various galenic dosage forms]. ( Ramadori, G; Schwörer, H, 2000)
"Of 112 cases of ulcerative colitis observed, 95 showed no change in extent and were studied as examples of non-progressive UC, and in this group the extension of the disease was: pancolitis in 19%, left-sided colitis in 39%, proctosigmoiditis in 17% and proctitis in 25%."	1.30	Evaluation of clinical patterns in ulcerative colitis: a long-term follow-up. ( Banti, S; Bertoni, M; Bresci, G; Capria, A; Gambardella, L; Parisi, G; Rindi, G, 1997)
"Two patients with Crohn's disease who had hypercalcemia, hypercalciuria, and excessively high serum levels of 1,25-dihydroxyvitamin D [1,25(OH)2D] are described."	1.30	Hypercalcemia due to endogenous overproduction of 1,25-dihydroxyvitamin D in Crohn's disease. ( Bosch, X, 1998)
"Thirty children operated on for Crohn's disease (CD) were reviewed (1975-1994)."	1.30	Postoperative outcome of Crohn's disease in 30 children. ( Aigrain, Y; Besnard, M; Cézard, JP; Debrun, A; Delagausie, P; Faure, C; Ferkdadji, L; Jaby, O; Mougenot, JF; Navarro, J; Peuchmaur, M, 1998)
"Surgical resection of Crohn's disease is followed by early recurrence in a high percentage of patients."	1.30	Prevention of post-operative recurrence of Crohn's disease requires adequate mucosal concentration of mesalazine. Gruppo Italiano per lo Studio del Colon e del Retto. ( Andreoli, A; Annese, V; Caprilli, R; Comberlato, M; Corrao, G; Frieri, G; Palumbo, G; Pimpo, MT; Sturniolo, GC; Tonelli, F, 1999)
"Discontinuation of 6MP, while Crohn's disease is in remission, leads to higher relapse rates and continuation of 6MP reduces the likelihood of relapse."	1.30	Optimum duration of treatment with 6-mercaptopurine for Crohn's disease. ( Gleim, GW; Kim, PS; Korelitz, BI; Zlatanic, J, 1999)
"After 12 months recurrences were observed in 14 of 15 patients initially treated with steroids and in 7 of 15 subjects who were had received transdermal nicotine (P = 0."	1.30	Long-term effects of a single course of nicotine treatment in acute ulcerative colitis: remission maintenance in a 12-month follow-up study. ( Guslandi, M, 1999)
"In Crohn's disease as well as in ulcerative colitis steroids are of major importance in the treatment of active disease."	1.29	[Current therapeutic possibilities in chronic inflammatory intestinal diseases]. ( Schölmerich, J, 1995)
"Crohn's recurrence is the appearance of objective signs--defined radiologically, endoscopically or pathologically--of Crohn's disease in the bowel of a patient who has previously had a resection of all macroscopically diseased tissue."	1.29	Recurrence of Crohn's disease in the neoterminal ileum after ileal resection: is prevention therapy possible? ( Rutgeerts, P, 1994)
"To determine the long term outcome of ulcerative colitis in patients treated with 6-MP."	1.29	The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. ( Bodian, C; George, J; Pou, R; Present, DH; Rubin, PH, 1996)
"The treatment of pneumothorax is difficult if the ulcerative colitis requires corticosteroids."	1.29	[Bilateral pneumothorax and hemorrhagic rectocolitis]. ( David, V; Heloury, Y; Nomballais, MF; Plattner, V, 1996)
"In patients with Crohn's disease with ileal involvement, relapse rates were sulphasalazine 9/28 (32."	1.28	Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis? ( Duncan, A; Nakshabendi, IM; Russell, RI, 1992)
"Treatment with mesalamine enemas allowed patients to decrease or discontinue glucocorticoid treatment."	1.28	Long-term use of mesalamine enemas to induce remission in ulcerative colitis. ( Biddle, WL; Miner, PB, 1990)

Research

Studies (269)

Authors

Clinical Trials (27)

Trial Overview

Trial Outcomes

Change in GSS From Baseline to Week 12 - ITT Population

Timeframe	Studies, this research(%)	All Research%
pre-1990	7 (2.60)	18.7374
1990's	72 (26.77)	18.2507
2000's	77 (28.62)	29.6817
2010's	100 (37.17)	24.3611
2020's	13 (4.83)	2.80

Authors	Studies
Caron, B	1
Sandborn, WJ	3
Panaccione, R	1
Schreiber, S	4
Hart, A	1
Solitano, V	1
Danese, S	5
Peyrin-Biroulet, L	4
Arkenbosch, JHC	1
Mak, JWY	1
Ho, JCL	1
Beelen, EMJ	1
Erler, NS	1
Hoentjen, F	2
Bodelier, AGL	1
Dijkstra, G	1
Romberg-Camps, M	1
de Boer, NKH	1
Stassen, LPS	1
van der Meulen, AE	1
West, R	1
van Ruler, O	1
van der Woude, CJ	2
Ng, SC	1
de Vries, AC	1
Akturk, R	1
Serinsöz, S	1
Mahmoud, R	1
Savelkoul, EHJ	1
Mares, W	1
Goetgebuer, R	1
Witteman, BJM	1
de Koning, DB	1
van Tuyl, SAC	1
Minderhoud, I	1
Lutgens, MWMD	1
Akol-Simsek, D	1
van Schaik, FDM	1
Fidder, HH	1
Jansen, JM	1
van Boeckel, PGA	1
Mahmmod, N	1
Horjus-Talabur Horje, CS	1
Römkens, TEH	1
Colombel, JF	3
Jharap, B	1
Oldenburg, B	1
Johnsen, KM	3
Florholmen, J	3
Moe, ØK	3
Gundersen, M	3
Beilfuss, J	3
Kileng, H	3
Sørbye, SW	3
Goll, R	3
Rojo, E	1
Casanova, MJ	2
Gisbert, JP	6
Iheozor-Ejiofor, Z	2
Kaur, L	1
Gordon, M	2
Baines, PA	1
Sinopoulou, V	1
Akobeng, AK	2
Candia, R	1
Bravo-Soto, GA	1
Monrroy, H	1
Hernandez, C	1
Nguyen, GC	3
Murray, A	1
Nguyen, TM	1
Parker, CE	2
Feagan, BG	3
MacDonald, JK	3
Narula, N	1
Aruljothy, A	1
Alshahrani, AA	1
Fadida, M	1
Al-Saedi, M	1
Marshall, JK	1
Rubin, DT	2
Christensen, B	1
Orlando, A	2
Mocciaro, F	2
Ventimiglia, M	1
Renna, S	2
Rispo, A	2
Scribano, ML	2
Testa, A	2
Aratari, A	2
Bossa, F	2
Angelucci, E	2
Onali, S	2
Cappello, M	2
Giunta, M	1
Scimeca, D	2
Macaluso, FS	1
Castiglione, F	3
Papi, C	3
Annese, V	5
Biancone, L	2
Kohn, A	3
Di Mitri, R	1
Cottone, M	6
Hegyi, PJ	1
Szakács, Z	1
Faluhelyi, N	1
Németh, BC	1
Bajor, J	1
Hegyi, P	2
Madarame, A	1
Fukuzawa, M	1
Yamauchi, Y	1
Kono, S	1
Sugimoto, A	1
Yamaguchi, H	1
Morise, T	1
Koyama, Y	1
Uchida, K	2
Suguro, M	1
Matsumoto, T	1
Yasuyuki, K	1
Kawai, T	1
Itoi, T	1
Festa, V	1
Spila Alegiani, S	1
Chiesara, F	1
Moretti, A	1
Bianchi, M	1
Dezi, A	1
Traversa, G	1
Koch, M	1
Nagahori, M	1
Kochi, S	1
Hanai, H	3
Yamamoto, T	5
Nakamura, S	1
Omuro, S	1
Watanabe, M	1
Hibi, T	1
Kruis, W	4
Kardalinos, V	1
Eisenbach, T	1
Lukas, M	3
Vich, T	1
Bunganic, I	1
Pokrotnieks, J	2
Derova, J	1
Kondrackiene, J	1
Safadi, R	1
Tuculanu, D	1
Tulassay, Z	1
Banai, J	1
Curtin, A	1
Dorofeyev, AE	1
Zakko, SF	1
Ferreira, N	1
Björck, S	1
Diez Alonso, MM	1
Mäkelä, J	1
Talley, NJ	1
Dilger, K	1
Greinwald, R	2
Mohrbacher, R	1
Spiller, R	1
Urushidani, S	1
Kuriyama, A	1
Matsumura, M	2
Singh, S	1
Allocca, M	1
Landi, R	1
Bonovas, S	1
Fiorino, G	2
Papa, A	3
Spinelli, A	2
Furfaro, F	1
Armuzzi, A	1
Doherty, G	1
Katsanos, KH	1
Burisch, J	3
Allez, M	1
Papamichael, K	1
Stallmach, A	1
Mao, R	1
Berset, IP	1
Sebastian, S	1
Kierkus, J	1
Lopetuso, L	1
Szymanska, E	1
Louis, E	2
Fukuda, T	1
Naganuma, M	1
Sugimoto, S	1
Nanki, K	1
Mizuno, S	1
Mutaguchi, M	1
Nakazato, Y	1
Inoue, N	1
Ogata, H	1
Iwao, Y	1
Kanai, T	1
Garcia-Planella, E	3
Mañosa, M	4
Chaparro, M	3
Beltrán, B	2
Barreiro-de-Acosta, M	1
Gordillo, J	2
Ricart, E	1
Bermejo, F	2
García-Sánchez, V	2
Piqueras, M	1
Llaó, J	2
Cabré, E	3
Domènech, E	4
Ribaldone, DG	1
Vernero, M	1
Saracco, GM	1
Pellicano, R	2
Finocchiaro, F	1
Caviglia, GP	1
Astegiano, M	1
Khan, RMA	1
Ali, B	2
Hajibandeh, S	2
Lin, Z	1
Zhu, B	1
Jin, X	1
Ray, G	1
Kluthe, C	1
Tsui, J	1
Spady, D	1
Carroll, M	1
Wine, E	1
Huynh, HQ	1
Meczker, Á	1
Mikó, A	1
Kikuchi, H	1
Sakuraba, H	1
Akemoto, Y	1
Murai, Y	1
Fukutoku, Y	1
Asari, T	1
Tatsuta, T	1
Hasui, K	1
Hiraga, H	1
Sawaya, M	1
Chinda, D	1
Mikami, T	1
Tanaka, M	1
Fukuda, S	1
Ballester, MP	1
Marti-Aguado, D	1
Fullana, M	1
Bosca-Watts, MM	1
Tosca, J	2
Romero, E	1
Sanchez, A	1
Navarro-Cortes, P	1
Anton, R	1
Mora, F	1
Minguez, M	1
Park, M	1
Lee, J	1
Kang, SB	1
Park, Y	2
Gjuladin-Hellon, T	1
Carabotti, M	1
Annibale, B	1
Stollman, N	1
Magowan, S	1
Shanahan, F	1
Quigley, EM	1
Ren, J	1
Wu, X	1
Liao, N	1
Wang, G	1
Fan, C	1
Liu, S	1
Ren, H	1
Zhao, Y	1
Li, J	2
Parente, F	1
Bargiggia, S	1
Prada, A	1
Bortoli, A	1
Giacosa, A	1
Germanà, B	1
Ferrari, A	1
Casella, G	1
De Pretis, G	1
Miori, G	1
Robinson, A	2
Hankins, M	1
Wiseman, G	1
Jones, M	1
Rodríguez-Grau, Mdel C	1
Díaz, R	1
Kanazawa, A	1
Sako, M	1
Takazoe, M	1
Tadami, T	1
Kawaguchi, T	1
Yoshimura, N	1
Okamoto, K	1
Yamana, T	1
Sahara, R	1
Gillespie, D	1
Hood, K	1
Farewell, D	1
Stenson, R	1
Probert, C	1
Hawthorne, AB	1
Shiraki, M	1
Bamba, T	2
Umegae, S	3
Matsumoto, K	4
Yang, Z	1
Ye, X	1
Wu, Q	1
Wu, K	1
Fan, D	1
Subramaniam, K	1
Richardson, A	1
Dodd, J	1
Platten, J	1
Shadbolt, B	1
Pavli, P	1
Zabana, Y	2
Bernal, I	1
Marín, L	1
Lorenzo-Zúñiga, V	1
Moreno, V	1
Boix, J	1
Lia Scribano, M	1
Tambasco, R	1
Fries, W	1
D'Incà, R	2
Martinato, M	1
Gionchetti, P	4
Rizzello, F	3
Vernia, P	1
Tursi, A	9
Osterman, MT	1
Aberra, FN	1
Cross, R	1
Liakos, S	1
McCabe, R	1
Shafran, I	1
Wolf, D	1
Hardi, R	1
Nessel, L	1
Brensinger, C	1
Gilroy, E	1
Lewis, JD	1
Hojsak, I	1
Pavić, AM	1
Kolaček, S	1
Takeshima, F	1
Makiyama, K	1
Ohba, K	1
Yamakawa, M	1
Nishiyama, H	1
Yamao, T	1
Akazawa, Y	1
Yamaguchi, N	1
Ohnita, K	1
Ichikawa, T	1
Isomoto, H	1
Nakao, K	1
Bodini, G	1
Savarino, V	2
de Cassan, C	1
Dulbecco, P	1
Baldissarro, I	1
Fazio, V	1
Giambruno, E	1
Savarino, E	1
Pedersen, N	1
Thielsen, P	1
Martinsen, L	1
Bennedsen, M	1
Haaber, A	1
Langholz, E	1
Végh, Z	1
Duricova, D	1
Jess, T	2
Bell, S	1
Munkholm, P	2
Vidigal, FM	1
de Souza, GS	1
Chebli, LA	1
da Rocha Ribeiro, TC	1
Furtado, MC	1
Castro, AC	1
Pinto, AL	1
do Valle Pinheiro, B	1
de Lima Pace, FH	1
Machado de Oliveira, J	1
de Oliveira Zanini, KA	1
Gaburri, PD	1
Zanini, A	1
Ribeiro, LC	1
Chebli, JM	1
Carla-Moreau, A	1
Paul, S	1
Roblin, X	1
Genin, C	1
Kaye, TL	1
O'Connor, A	1
Burke, D	1
Tolan, DJ	1
Bain, JA	1
Shimoyama, T	1
Pica, R	2
Cassieri, C	1
Cocco, A	1
Zippi, M	1
Marcheggiano, A	2
De Nitto, D	1
Avallone, EV	1
Crispino, P	2
Occhigrossi, G	1
Paoluzi, P	4
Sun, J	1
Shen, X	1
Dong, J	1
Wang, H	1
Zuo, L	1
Zhao, J	1
Zhu, W	1
Li, Y	1
Gong, J	1
Bollen, L	1
Vande Casteele, N	1
Ballet, V	1
van Assche, G	1
Ferrante, M	1
Vermeire, S	2
Gils, A	1
Lichtenstein, GR	5
Gordon, GL	2
Zakko, S	2
Murthy, U	2
Sedghi, S	2
Pruitt, R	2
Barrett, AC	1
Bortey, E	2
Paterson, C	1
Forbes, WP	2
Eliadou, E	1
Day, AS	1
Thompson-Fawcett, MW	1
Gearry, RB	2
Rowbotham, DS	1
Walmsley, R	1
Schultz, M	2
Inns, SJ	1
Losurdo, G	1
Iannone, A	1
Contaldo, A	1
Ierardi, E	1
Di Leo, A	1
Principi, M	1
Prosberg, MV	1
Vester-Andersen, MK	1
Andersson, M	1
Andersen, JT	1
Vind, I	1
Bendtsen, F	1
Kim, JH	1
Cheon, JH	4
Lee, HJ	1
Park, SJ	2
Kim, TI	4
Kim, WH	4
Karstensen, JG	1
Săftoiu, A	1
Brynskov, J	1
Hendel, J	1
Ciocalteu, A	1
Klausen, P	1
Klausen, TW	1
Riis, LB	1
Vilmann, P	1
Puga, M	1
Carpio, D	1
Sampil, M	1
Zamora, MJ	1
Fernandez-Salgado, E	1
Khan, MA	1
Lee, WM	1
Howden, CW	1
Wang, Y	1
Razik, R	1
Rumman, A	1
Bahreini, Z	1
McGeer, A	1
Roose, L	1
D'cunja, J	1
Biedermann, L	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Observational Study on Clinical Practice in the Management of Ulcerative Colitis With Oral 5-Aminosalicylic Acid in Japan[NCT01654783]		5,704 participants (Actual)	Observational	2012-09-30	Completed
Double-blind, Randomized, Placebo-controlled, Parallel Group, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis[NCT00695643]	Phase 3	345 participants (Actual)	Interventional	2008-01-31	Terminated
Double-blind, Dose-response, Randomised, Placebo-controlled, Parallel Group, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Mesalazine Granules vs. Placebo for the Prevention of Recurrence of Diverticulitis[NCT01038739]	Phase 3	330 participants (Actual)	Interventional	2010-01-31	Terminated (stopped due to Stopped due to futility.)
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of a 12 Week Treatment of Acute Diverticulitis With Asacol® 2.4 g/Day (400 mg Mesalamine Tablet), Followed by a 9 Month Treatment-free Observation Period[NCT00554099]	Phase 2	117 participants (Actual)	Interventional	2007-11-30	Completed
[NCT01120340]	Phase 3	105 participants (Actual)	Interventional	2005-10-31	Completed
MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)[NCT04578392]		181 participants (Anticipated)	Interventional	2020-07-28	Recruiting
Test Treat Strategy to Prevent Ulcerative Colitis Relapse[NCT00652145]	Phase 4	119 participants (Actual)	Interventional	2008-09-30	Completed
Reduction in Length of Hospitalization in Patients With Acute Severe Ulcerative Colitis Treated With Rescue Therapy With Infliximab by the Use of Web-app Constant-Care. One Year Follow-up, Inclusive Colectomy Rate.[NCT04165265]		28 participants (Anticipated)	Interventional	2019-12-03	Recruiting
Role of Information and Communication Technologies for Health Support in Inflammatory Bowel Diseases: The DAMASCO Trial (Stage I)[NCT04893928]		351 participants (Anticipated)	Observational	2021-05-03	Recruiting
Individualization of Oral Mesalazine Treatment Through a Self-managed Web-based Solution in Mild-to-moderate Ulcerative Colitis: A Pilot Study[NCT03604536]		1 participants (Actual)	Observational	2019-12-02	Terminated (stopped due to not able to recruit patients)
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Use of Mesalamine Pellet Formulation 1.5G QD to Maintain Remission From Mild to Moderate Ulcerative Colitis[NCT00744016]	Phase 3	305 participants (Actual)	Interventional	2004-12-31	Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Use of Mesalamine Pellet Formulation 1.5G QD to Maintain Remission From Mild to Moderate Ulcerative Colitis[NCT00767728]	Phase 3	256 participants (Actual)	Interventional	2004-12-31	Completed
A Multicenter, Open-Label, Treatment Extension Trial to Evalaute the Long-Term Safety and Tolerability of Mesalamine Pellet Formulation[NCT00326209]	Phase 3	393 participants (Actual)	Interventional	2005-12-22	Completed
Confocal Laser Endomicroscopy Findings in Patients With Proctosigmoiditis Before and After Initiation of Treatment[NCT01684514]		29 participants (Actual)	Interventional	2012-10-31	Completed
Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: Multicentre, Prospective, Randomized Clinical Trial and Economic Evaluation[NCT02994836]	Phase 4	139 participants (Actual)	Interventional	2017-04-21	Completed
A Randomized, Controlled, Open-label Study to Investigate the Impact of Disease Activity and Nutrition Treat on Postoperative Recurrence and Complications After Bowel Resection for Crohn's Disease[NCT01540942]		91 participants (Actual)	Interventional	2011-11-30	Completed
"A Phase 1b/2 Study to Demonstrate the Safety and Efficacy of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an Ileal Pouch-Anal Anastomosis (PROF). The PROF Study."[NCT05938465]	Phase 1/Phase 2	50 participants (Anticipated)	Interventional	2023-10-11	Recruiting
A Phase IV, Multi-center, Open-label Study to Assess Clinical Recurrence Related to Compliance With Treatment With MMX Mesalamine 2.4g/Day Given Once Daily for the Maintenance of Quiescent Ulcerative Colitis (UC)[NCT00446849]	Phase 4	290 participants (Actual)	Interventional	2007-05-01	Completed
Efficacy of High-dose Corticosteroid Pulses Added to Conventional Oral Corticosteroid Course for Moderate Flares of Ulcerative Colitis.[NCT02921555]	Phase 4	75 participants (Actual)	Interventional	2018-10-11	Completed
Clinical Trial to Assess the Efficacy and Safety of Adding GMA to Infliximab in Paediatric Patients With Steroid-refractory Ulcerative Colitis[NCT05430412]		15 participants (Anticipated)	Interventional	2022-01-11	Recruiting
A Double-blind, Randomized, Placebo-Controlled Trial of Curcumin Versus Placebo for Prevention of Relapse in Patients With Ulcerative Colitis[NCT03122613]		29 participants (Actual)	Interventional	2017-06-19	Terminated (stopped due to Decision made by team of investigators)
The Effects of Daily Anti-inflammatory Supplementation on Foundation Pain Index Scores in Chronic Opiate Patients[NCT05896878]		20 participants (Anticipated)	Interventional	2023-07-10	Enrolling by invitation
Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Adults on Antibiotics[NCT00848003]	Phase 1	40 participants (Actual)	Interventional	2009-10-31	Completed
A Phase III, Randomized, Multi-center, Open-label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of SPD476 (Mesalazine) Given Once Daily vs. Twice Daily for the Maintenance of Ulcerative Colitis in Remission.[NCT00151944]	Phase 3	400 participants	Interventional	2003-11-26	Completed
Risk-stratified Randomized Controlled Trial in Paediatric Crohn Disease:Methotrexate vs Azathioprine or Adalimumab for Maintaining Remission in Patients at Low or High Risk for Aggressive Disease Course, respectively-a Treatment Strategy[NCT02852694]	Phase 4	312 participants (Anticipated)	Interventional	2017-02-28	Recruiting
Valutazione Dell'Efficacia Di Una Preparazione Commerciale A Base Di Lactobacillus Casei Dg Nella Riduzione Della Sintomatologia Dolorosa Associata Alla Sindrome Dell' Intestino Irritabile (Sii). Studio Clinico Pilota. (Official Title in Italian Language)[NCT02077699]	Phase 4	10 participants (Actual)	Interventional	2012-03-31	Completed
Electronic Linkage for Inflammatory Bowel Disease to Deliver Joint Access to Health Reports[NCT02985476]		61 participants (Actual)	Interventional	2010-05-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

GSS - Abdominal Pain & Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse). (NCT00554099)
Timeframe: Baseline to Week 12

Change in GSS From Baseline to Week 52 - ITT Population

Intervention	Scores on a Scale (Mean)
Placebo	-16.14
Mesalamine	-17.63
Mesalamine & Probiotic	-16.11

Global Symptom Score (GSS) at Week 12, Primary Efficacy Population

Intervention	Scores on a Scale (Mean)
Placebo	-16.82
Mesalamine	-17.30
Mesalamine & Probiotic	-16.00

Percentage of Responders at Week 12 - ITT Population

Intervention	Scores on a Scale (Mean)
Placebo	7.3
Mesalamine	4.4
Mesalamine & Probiotic	5.9

Responder - patient whose GSS scores for all symptoms were either 0 or 1 GSS - Abdominal Pain & Symptom Rating, scale 0-none (better) to 6-severe (worse) for each of the following categories: abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus in stool, feeling urge to evacuate but no bowel movement, painful straining with bowel movement, pain/difficulty urinating. Total minimum score 0 (better), total maximum score 60 (worse). (NCT00554099)
Timeframe: 12 Weeks

Percentage of Responders at Week 52 - ITT Population

Intervention	Percentage of Participants (Number)
Placebo	41.4
Mesalamine	62.5
Mesalamine & Probiotic	48.1

Recurrent Diverticulitis, Percentage, ITT Population, Week 12

Intervention	Percentage of Participants (Number)
Placebo	50.0
Mesalamine	66.7
Mesalamine & Probiotic	29.2

At least one report of recurrent diverticulitis since the last visit (prior to the Week 12 visit). (NCT00554099)
Timeframe: 12 Weeks

Recurrent Diverticulitis, Percentage, ITT Population, Week 52

Intervention	Percentage of Participants (Number)
Placebo	20.0
Mesalamine	12.5
Mesalamine & Probiotic	11.8

At least one report of recurrent diverticulitis since the last visit (prior to the Week 52 visit). (NCT00554099)
Timeframe: 52 Weeks

Withdrawal Due to Surgery for Diverticulitis, Percentage, ITT Population, Week 12

Fecal Calprotectin <200 µg/g

Fecal Calprotectin Level <100 µg/g

Fecal Calprotectin Level <50µg/g

Number of Participants Who Prematurely Discontinued Treatment

Intervention	Percentage of Participants (Number)
Placebo	31.0
Mesalamine	28.1
Mesalamine & Probiotic	37.0

Intervention	Percentage of Participants (Number)
Placebo	2.4
Mesalamine	5.0
Mesalamine & Probiotic	0.0

Intervention	participants (Number)
Increase Dose of Mesalamine	10
Maintain Baseline Mesalamine Dose	2

Intervention	participants (Number)
Increase Dose of Mesalamine	10
Maintain Baseline Mesalamine Dose	3

Intervention	participants (Number)
Increase Mesalamine Dose by 2.4g/Day	7
Maintain Mesalmine Dose	1

Number of participants who prematurely discontinued treatment due to any reason were reported. (NCT00326209)
Timeframe: Baseline up to Month 24

Number of Participants With Clinically Significant Change From Baseline in Vital Signs

Intervention	Participants (Count of Participants)
Encapsulated Mesalamine Granules (eMG)	282

Vital signs included systolic and diastolic blood pressure, pulse rate, body temperature, or body weight. (NCT00326209)
Timeframe: Baseline, up to follow-up visit (Month 24.5)

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

Intervention	Participants (Count of Participants)
Encapsulated Mesalamine Granules (eMG)	0

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A TEAE was defined as any event with a start date occurring on or after treatment Day 1 or, if pre-existing, worsening after treatment Day 1. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section. (NCT00326209)
Timeframe: Baseline (Day 1) up to follow-up (24.5 months)

Number of Participants With Potentially Clinically Significant (PCS) Hematology and Blood Chemistry Abnormalities

Intervention	Participants (Count of Participants)
Encapsulated Mesalamine Granules (eMG)	280

Criteria for potentially clinically significant abnormal hematology and blood chemistry values included: hemoglobin (grams/deciliter [g/dL]): <10 and ≥3 decrease, or >20; hematocrit (%): <30 and ≥10 decrease, or >60; platelets (*10^9 cells/liter): <100 or >700 (normal: 150-400); white blood cells (*10^9 cells/liter): <2.3 or >16.2 (normal: 3.5-11.1); alanine aminotransferase (units/liter [U/L]): ≥3 * upper limit of normal (ULN) (normal range 0-47 U/L); aspartate aminotransferase (U/L): ≥3 * ULN (normal range 0-37 U/L); total bilirubin (micromoles/liter [µmol/L]): >2 times; and calcium creatinine clearance (milliliters/minute [mL/min]): ≤50. (NCT00326209)
Timeframe: Baseline up to follow-up (24.5 months)

Endoscopic Remission of UC During the Maintenance Phase at 12 Months

Intervention	Participants (Count of Participants)
	Hemoglobin (g/dL)	Hematocrit (%)	Platelets (*10^9 cells/L)	White blood cells (*10^9 cells/L)	Alanine aminotransferase (U/L)	Aspartate aminotransferase (U/L)	Total bilirubin (µmol/L)	Calcium creatinine clearance (mL/min)
Encapsulated Mesalamine Granules (eMG)	8	7	5	13	3	3	6	2

Endoscopic remission is defined as an endoscopy score of less than or equal to 1. Endoscopy score (mucosal appearance) ranges from 0-3 (0 = normal [intact vascular pattern; no friability or granulation], 1 = mild [erythema; decreased vascular pattern; minimal granularity], 2 = moderate [marked erythema; granularity; friability; absent vascular pattern; bleeding with minimal trauma; no ulcerations], 3 = severe [ulceration; spontaneous bleeding]. (NCT00446849)
Timeframe: 12 Months

Quiescent UC During the Maintenance Phase at 12 Months

Intervention	Participants (Number)
MMX Mesalamine (Maintenance Phase)	124

Quiescent UC is defined as scores of 0 for both rectal bleeding and bowel movements. Rectal bleeding is assessed on a scale from 0-3 (0 = no rectal bleeding, 1 = streaks of blood, 2 = obvious blood, 3 = mostly blood). Bowel movements are assessed on a scale of 0-2 (0 = 0-1 more than normal per day, 1 = 2-3 more than normal per day, 2 = 4 or more than normal per day). (NCT00446849)
Timeframe: 12 Months

Clinical Recurrence of UC During the Maintenance Phase Associated With Subject Compliance at 12 Months

Intervention	Participants (Number)
MMX Mesalamine (Maintenance Phase)	101

Clinical recurrence is defined as 4 or more bowel movements per day above the subject's normal frequency and associated with any of the following: urgency, abdominal pain, or rectal bleeding. Compliance is a subject's adherence to a recommended course of treatment and for this study is calculated: (Sum of days' supplies dispensed) divided by (Sum of days in all refill intervals) x 100. (NCT00446849)
Timeframe: 12 months

Clinical Recurrence of UC During the Maintenance Phase Associated With Subject Compliance at 6 Months

Intervention	Percent of participants (Number)
	< 80% Compliant (n = 40)	80-120% Compliant (n = 154)
MMX Mesalamine (Maintenance Phase)	52.5	31.2

Clinical recurrence is defined as 4 or more bowel movements per day above the subject's normal frequency and associated with any of the following: urgency, abdominal pain, or rectal bleeding. Compliance is a subject's adherence to a recommended course of treatment and for this study is calculated: [(Sum of days' supplies dispensed) divided by (Sum of days in all refill intervals)] x 100. (NCT00446849)
Timeframe: 6 Months

Clinical Recurrence of UC During the Maintenance Phase at 12 Months

Intervention	Percent of participants (Number)
	< 80% Compliant (n = 36)	80-120% Compliant (n = 158)	> 120% Compliant (n = 2)
MMX Mesalamine (Maintenance Phase)	36.1	20.9	0

Clinical Recurrence of Ulcerative Colitis (UC) During the Maintenance Phase at 6 Months

Article	Year
Efficacy of Pharmacological Agents for Ulcerative Proctitis: A Systematic Literature Review. Journal of Crohn's & colitis, 2022, Jul-14, Volume: 16, Issue:6 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesalamine; Observation	2022
Treatment of microscopic colitis: the role of budesonide and new alternatives for refractory patients. Revista espanola de enfermedades digestivas, 2020, Volume: 112, Issue:1 Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antidiarrheals; Antimetabolites; Azathioprine; Bi	2020
Probiotics for maintenance of remission in ulcerative colitis. The Cochrane database of systematic reviews, 2020, 03-04, Volume: 3 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans	2020
Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease. The Cochrane database of systematic reviews, 2020, 08-03, Volume: 8 Topics: Adalimumab; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Asymptomatic Dise	2020
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. The Cochrane database of systematic reviews, 2020, 08-28, Volume: 8 Topics: Administration, Oral; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Bias; Colitis,	2020
5-aminosalicylic acid agents for prevention of recurrent diverticulitis: A systematic review and meta-analysis. Journal of gastroenterology and hepatology, 2018, Volume: 33, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Anti-Inflammatory Agents; Database	2018
Management of Crohn's Disease After Surgical Resection. Gastroenterology clinics of North America, 2017, Volume: 46, Issue:3 Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colonoscopy; Crohn Disease; Digestive System Su	2017
European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease. Journal of Crohn's & colitis, 2018, Jan-05, Volume: 12, Issue:1 Topics: Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Colitis, Ulcerative; Conse	2018
Effect of mesalazine on recurrence of diverticulitis in patients with symptomatic uncomplicated diverticular disease: a meta-analysis with trial sequential analysis of randomized controlled trials. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2018, Volume: 20, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Diverticulitis, Colonic; Diverticulosis, Colonic; Humans; M	2018
5-ASA induces mild acute pancreatitis. Case report and review of the literature. Journal of gastrointestinal and liver diseases : JGLD, 2018, Volume: 27, Issue:2 Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Mesalamine; Pancreati	2018
Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. The Cochrane database of systematic reviews, 2019, 06-20, Volume: 6 Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease; Humans; Mesalamine; Qu	2019
Mesalamine (5-ASA) for the prevention of recurrent diverticulitis (Review). Techniques in coloproctology, 2019, Volume: 23, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Diverticulitis; Humans; Mesalamine; Recurrence; Secondary P	2019
A network meta-analysis on the efficacy of 5-aminosalicylates, immunomodulators and biologics for the prevention of postoperative recurrence in Crohn's disease. International journal of surgery (London, England), 2014, Volume: 12, Issue:5 Topics: Biological Products; Crohn Disease; Humans; Immunologic Factors; Mesalamine; Randomized Controlled T	2014
New physiopathological and therapeutic approaches to diverticular disease: an update. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:7 Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colon; Dietary Fiber; Diver	2014
Prevention and treatment of postoperative Crohn's disease recurrence with anti-TNF therapy: a meta-analysis of controlled trials. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Crohn Disease; Humans; Immunosuppre	2015
A young woman with recurrent perianal sepsis. BMJ (Clinical research ed.), 2015, Apr-23, Volume: 350 Topics: Abscess; Adult; Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease; Drainage; Female; Humans; Ma	2015
Review article: the pathophysiology and medical management of diverticulosis and diverticular disease of the colon. Alimentary pharmacology & therapeutics, 2015, Volume: 42, Issue:6 Topics: Anti-Bacterial Agents; Dietary Fiber; Diverticulitis, Colonic; Diverticulum; Humans; Mesalamine; Pro	2015
Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission. Digestive diseases and sciences, 2016, Volume: 61, Issue:1 Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Clinical Trials, Phase III as Topic; Colit	2016
Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission. Digestive diseases and sciences, 2016, Volume: 61, Issue:1 Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Clinical Trials, Phase III as Topic; Colit	2016
Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission. Digestive diseases and sciences, 2016, Volume: 61, Issue:1 Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Clinical Trials, Phase III as Topic; Colit	2016
Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission. Digestive diseases and sciences, 2016, Volume: 61, Issue:1 Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Clinical Trials, Phase III as Topic; Colit	2016
Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission. Digestive diseases and sciences, 2016, Volume: 61, Issue:1 Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Clinical Trials, Phase III as Topic; Colit	2016
Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission. Digestive diseases and sciences, 2016, Volume: 61, Issue:1 Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Clinical Trials, Phase III as Topic; Colit	2016
Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission. Digestive diseases and sciences, 2016, Volume: 61, Issue:1 Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Clinical Trials, Phase III as Topic; Colit	2016
Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission. Digestive diseases and sciences, 2016, Volume: 61, Issue:1 Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Clinical Trials, Phase III as Topic; Colit	2016
Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission. Digestive diseases and sciences, 2016, Volume: 61, Issue:1 Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Clinical Trials, Phase III as Topic; Colit	2016
Escherichia coli Nissle 1917 in Ulcerative Colitis Treatment: Systematic Review and Meta-analysis. Journal of gastrointestinal and liver diseases : JGLD, 2015, Volume: 24, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Chi-Square Distribution; Colitis, Ulcerative; Colon; Escher	2015
Mesalamine Does Not Help Prevent Recurrent Acute Colonic Diverticulitis: Meta-Analysis of Randomized, Placebo-Controlled Trials. The American journal of gastroenterology, 2016, Volume: 111, Issue:4 Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Diverticulitis, Colonic; Humans; Mesalamine;	2016
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. The Cochrane database of systematic reviews, 2016, May-09, Issue:5 Topics: Administration, Oral; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcera	2016
[Ulcerative colitis]. Praxis, 2016, May-25, Volume: 105, Issue:11 Topics: Administration, Rectal; Adrenal Cortex Hormones; Algorithms; Colitis, Ulcerative; Colonoscopy; Diagn	2016
Mesalazine in preventing acute diverticulitis occurrence: a meta-analysis of randomized controlled trials. Journal of gastrointestinal and liver diseases : JGLD, 2016, Volume: 25, Issue:3 Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Chi-Square Distribution; Diverticulitis, Col	2016
[Postoperative recurrence of Crohn's disease, and its prevention]. Orvosi hetilap, 2010, May-23, Volume: 151, Issue:21 Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colonoscopy; Crohn Dis	2010
Risk of postoperative recurrence and postoperative management of Crohn's disease. World journal of gastroenterology, 2011, Jul-21, Volume: 17, Issue:27 Topics: Anastomosis, Surgical; Anti-Bacterial Agents; Budesonide; Crohn Disease; Endoscopy; Gastroenterology	2011
Fulminant ulcerative colitis despite maximal immunosuppression following liver transplantation: a case report and literature review. Journal of Crohn's & colitis, 2011, Volume: 5, Issue:5 Topics: Cholangitis, Sclerosing; Colectomy; Colitis, Ulcerative; Drug Therapy, Combination; Female; Humans;	2011
Recent advances in understanding ulcerative colitis. Internal and emergency medicine, 2012, Volume: 7, Issue:2 Topics: Biopsy, Needle; Colectomy; Colitis, Ulcerative; Colorectal Neoplasms; Combined Modality Therapy; Dis	2012
Systematic review of medical therapy to prevent recurrent diverticulitis. International journal of colorectal disease, 2012, Volume: 27, Issue:9 Topics: Anti-Bacterial Agents; Dietary Fiber; Diverticulitis; Humans; Mesalamine; Probiotics; Recurrence	2012
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. The Cochrane database of systematic reviews, 2012, Oct-17, Volume: 10 Topics: Administration, Oral; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcera	2012
Curcumin for maintenance of remission in ulcerative colitis. The Cochrane database of systematic reviews, 2012, Oct-17, Volume: 10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Curcumin; Drug Therapy, Combination; H	2012
[Can the postoperative relapse of Crohn disease be influenced?]. Duodecim; laaketieteellinen aikakauskirja, 2001, Volume: 117, Issue:8 Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Clinical Trials as Top	2001
[Conservative therapy of inflammatory bowel diseases]. Orvosi hetilap, 2002, Dec-15, Volume: 143, Issue:50 Topics: Acute Disease; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Chro	2002
[Management of ulcerative colitis]. Therapeutische Umschau. Revue therapeutique, 2003, Volume: 60, Issue:3 Topics: Administration, Oral; Adrenal Cortex Hormones; Aminosalicylic Acids; Anemia; Anti-Inflammatory Agent	2003
[5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2003, Sep-25, Volume: 123, Issue:18 Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Humans; Mesalamine; Rec	2003
Ulcerative colitis: conservative management and long-term effects. Langenbeck's archives of surgery, 2004, Volume: 389, Issue:5 Topics: Administration, Oral; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antibodies,	2004
Diagnosis and treatment of ulcerative proctitis. Journal of clinical gastroenterology, 2004, Volume: 38, Issue:9 Topics: Acute Disease; Diagnosis, Differential; Diarrhea; Hemorrhage; Humans; Mesalamine; Proctocolitis; Rec	2004
[Diverticulosis/diverticulitis? What are conservative therapy possibilities?]. Medizinische Klinik (Munich, Germany : 1983), 2006, Jan-15, Volume: 101, Issue:1 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-	2006
Systematic review: adherence issues in the treatment of ulcerative colitis. Alimentary pharmacology & therapeutics, 2006, Mar-01, Volume: 23, Issue:5 Topics: Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Attitude to H	2006
Review article: maintenance therapy in patients with ulcerative colitis. Alimentary pharmacology & therapeutics, 2006, Volume: 24 Suppl 1 Topics: Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc	2006
[Probiotics in chronic inflammatory bowel disease]. MMW Fortschritte der Medizin, 2006, Aug-31, Volume: 148, Issue:35-36 Topics: Anti-Inflammatory Agents, Non-Steroidal; Bifidobacterium; Colitis, Ulcerative; Crohn Disease; Escher	2006
Management of distal ulcerative colitis: frequently asked questions analysis. Internal medicine journal, 2008, Volume: 38, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Colitis, Ulcerative; Drug Admini	2008
Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitis. Reviews in gastroenterological disorders, 2008,Winter, Volume: 8, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesalamine; Recurrence; Risk F	2008
[Crohn disease: prevention and drug therapy]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 1995, Volume: 66, Issue:8 Topics: Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprin	1995
Maintenance of symptomatic remission in patients with Crohn's disease. Mayo Clinic proceedings, 1993, Volume: 68, Issue:12 Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Azathioprine; Clinical Trials as Topic; Crohn Disease	1993
[Long-term therapy of Crohn disease]. Der Internist, 1993, Volume: 34, Issue:12 Topics: Aminosalicylic Acids; Colon; Crohn Disease; Dose-Response Relationship, Drug; Drug Administration Sc	1993
[Treatment and recurrence prevention ulcerative colitis]. Der Internist, 1995, Volume: 36, Issue:12 Topics: Acute Disease; Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroida	1995
Is it possible to prevent recurrent Crohn's disease with medical or surgical interventions? The Netherlands journal of medicine, 1996, Volume: 48, Issue:2 Topics: Aminosalicylic Acids; Anastomosis, Surgical; Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease;	1996
[Postoperative recurrence in Crohn's disease]. Chirurgia italiana, 1995, Volume: 47, Issue:5 Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease; Humans; Mesalamine; Re	1995
Factors influencing the relapse of patients with inflammatory bowel disease. The American journal of gastroenterology, 1997, Volume: 92, Issue:12 Suppl Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Humans; Infections; Inflammatory Bowel Disea	1997
[Drug prevention of Crohn disease recurrence in the neo-terminal ileum after ileocolic resection]. Zentralblatt fur Chirurgie, 1998, Volume: 123, Issue:4 Topics: Anti-Inflammatory Agents; Budesonide; Colon; Crohn Disease; Follow-Up Studies; Humans; Ileum; Mesala	1998
Recurrent pericarditis due to mesalamine hypersensitivity: a pediatric case report and review of the literature. Journal of pediatric gastroenterology and nutrition, 1998, Volume: 27, Issue:3 Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Hypersensitivity; Hum	1998
[Therapy of Crohn disease in internal medicine: postoperative recurrence and fistulas]. Praxis, 1998, Nov-26, Volume: 87, Issue:48 Topics: Combined Modality Therapy; Crohn Disease; Female; Humans; Immunosuppressive Agents; Male; Mesalamine	1998
[Crohn disease--principle of longitudinal therapy planning with early surgical indications]. Langenbecks Archiv fur Chirurgie. Supplement. Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress, 1998, Volume: 115 Topics: Crohn Disease; Humans; Longitudinal Studies; Mesalamine; Patient Care Planning; Patient Care Team; P	1998
Mesalamine for the prevention of postoperative recurrence: is nearly there the same as being there? Gastroenterology, 2000, Volume: 118, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease; Humans; Mesalamine; Recurrence	2000
Medical therapy to reduce postoperative Crohn's disease recurrence. The American journal of gastroenterology, 2000, Volume: 95, Issue:5 Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease; Glucocorticoids; Huma	2000
Mesalamine and relapse prevention in Crohn's disease. Gastroenterology, 2000, Volume: 119, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease; Humans; Mesalamine; Recurrence; Risk Assessm	2000
[Guidelines of the DGVS. Acute process. German Society of Digestive and Metabolic Diseases]. Zeitschrift fur Gastroenterologie, 2001, Volume: 39, Issue:1 Topics: Acute Disease; Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents; Anti-Inflamma	2001
Conventional treatment of Crohn's disease: objectives and outcomes. Inflammatory bowel diseases, 2001, Volume: 7 Suppl 1 Topics: Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprin	2001
Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Digestive diseases and sciences, 2002, Volume: 47, Issue:3 Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida	2002
Maintenance treatment for Crohn's disease: has the time arrived? The American journal of gastroenterology, 1992, Volume: 87, Issue:5 Topics: Aminosalicylic Acids; Azathioprine; Crohn Disease; Drug Administration Schedule; Drug Therapy, Combi	1992
[Aminosalicylates in the treatment of chronic inflammatory bowel diseases]. Der Internist, 1990, Volume: 31, Issue:11 Topics: Aminosalicylic Acid; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Humans; Mesalamine; R	1990
[Prevention of recurrence of chronic inflammatory bowel diseases]. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1989, Volume: 95 Topics: Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Humans; Immunosu	1989

Article	Year
Azathioprine for prevention of clinical recurrence in Crohn's disease patients with severe endoscopic recurrence: an IG-IBD randomized double-blind trial. European review for medical and pharmacological sciences, 2020, Volume: 24, Issue:21 Topics: Azathioprine; Crohn Disease; Double-Blind Method; Humans; Mesalamine; Recurrence	2020
Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence. Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Diverticulitis; Double-Blind Method; Female; Humans; Male;	2017
Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence. Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Diverticulitis; Double-Blind Method; Female; Humans; Male;	2017
Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence. Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Diverticulitis; Double-Blind Method; Female; Humans; Male;	2017
Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence. Alimentary pharmacology & therapeutics, 2017, Volume: 46, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Diverticulitis; Double-Blind Method; Female; Humans; Male;	2017
A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. Journal of clinical gastroenterology, 2013, Volume: 47, Issue:7 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Bifidobacter	2013
Prevention of postoperative recurrence of Crohn's disease: Tripterygium wilfordii polyglycoside versus mesalazine. The Journal of international medical research, 2013, Volume: 41, Issue:1 Topics: Adult; Blood Sedimentation; C-Reactive Protein; Crohn Disease; Endoscopy; Female; Glycosides; Humans	2013
Intermittent treatment with mesalazine in the prevention of diverticulitis recurrence: a randomised multicentre pilot double-blind placebo-controlled study of 24-month duration. International journal of colorectal disease, 2013, Volume: 28, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Confidence Intervals; Demography; Diverticulitis; Double-Blind Metho	2013
Electronic monitoring of medication adherence in a 1-year clinical study of 2 dosing regimens of mesalazine for adults in remission with ulcerative colitis. Inflammatory bowel diseases, 2014, Volume: 20, Issue:1 Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dose-Resp	2014
Early post-operative endoscopic recurrence in Crohn's disease patients: data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort. Journal of Crohn's & colitis, 2014, Volume: 8, Issue:10 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colonoscopy; Crohn Disease; Female; Humans; Italy; M	2014
Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2014, Volume: 12, Issue:11 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Feces; Humans; Leukocyte L1 Ant	2014
Efficacy of long-term 4.0 g/day mesalazine (Pentasa) for maintenance therapy in ulcerative colitis. Medical science monitor : international medical journal of experimental and clinical research, 2014, Jul-27, Volume: 20 Topics: Cohort Studies; Colitis, Ulcerative; Dose-Response Relationship, Drug; Humans; Japan; Kaplan-Meier E	2014
Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:11 Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal, Humanized; Crohn Disease; Dose-Response Relationshi	2014
Azathioprine is more effective than mesalazine at preventing recurrent bowel obstruction in patients with ileocecal Crohn's disease. Medical science monitor : international medical journal of experimental and clinical research, 2014, Nov-05, Volume: 20 Topics: Adult; Azathioprine; Crohn Disease; Demography; Female; Humans; Ileocecal Valve; Intestinal Obstruct	2014
A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:11 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Biops	2015
Tripterygium wilfordii Hook F as Maintenance Treatment for Crohn's Disease. The American journal of the medical sciences, 2015, Volume: 350, Issue:5 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease; Dose-Response Relationship, Drug; Dru	2015
Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. Diseases of the colon and rectum, 2009, Volume: 52, Issue:5 Topics: Adult; Anastomosis, Surgical; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colon; Crohn Di	2009
Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. Diseases of the colon and rectum, 2009, Volume: 52, Issue:5 Topics: Adult; Anastomosis, Surgical; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colon; Crohn Di	2009
Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. Diseases of the colon and rectum, 2009, Volume: 52, Issue:5 Topics: Adult; Anastomosis, Surgical; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colon; Crohn Di	2009
Recurrence of Crohn's disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. Diseases of the colon and rectum, 2009, Volume: 52, Issue:5 Topics: Adult; Anastomosis, Surgical; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colon; Crohn Di	2009
Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Alimentary pharmacology & therapeutics, 2009, Nov-01, Volume: 30, Issue:9 Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-Actio	2009
[Maintenance effect of polyglycosides of Tripterygium wilfordii on remission in postoperative Crohn disease]. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2009, Volume: 12, Issue:5 Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease; Glycosides; Humans;	2009
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. The American journal of gastroenterology, 2010, Volume: 105, Issue:10 Topics: Adult; Azathioprine; Bifidobacterium; Colitis, Ulcerative; Combined Modality Therapy; Double-Blind M	2010
Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial. Alimentary pharmacology & therapeutics, 2010, Volume: 32, Issue:8 Topics: Adult; Colitis, Ulcerative; Double-Blind Method; Female; Hemorrhage; Humans; Male; Mesalamine; Middl	2010
High-dose mesalazine treatment for ulcerative colitis patients who relapse under low-dose maintenance therapy. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2011, Volume: 43, Issue:5 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonoscopy; Female; Humans; Ma	2011
Clinical course of microscopic colitis in a single-center cohort study. Journal of Crohn's & colitis, 2011, Volume: 5, Issue:3 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Cholestyramine Resin; Coho	2011
Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis. Inflammatory bowel diseases, 2012, Volume: 18, Issue:6 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Administration Schedule; F	2012
Nutritional therapy versus 6-mercaptopurine as maintenance therapy in patients with Crohn's disease. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2012, Volume: 44, Issue:8 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease; Food, Formulated; Humans; Immunosuppr	2012
Factors affecting short- and long-term effects of leukocyte removal therapy in active ulcerative colitis. Journal of gastroenterology and hepatology, 2013, Volume: 28, Issue:2 Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Child	2013
Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial. Alimentary pharmacology & therapeutics, 2003, Feb-15, Volume: 17, Issue:4 Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease; Dose-Response R	2003
[Comparative efficacy of mezakol and sulfasalazine in treating chronic relapsing ulcerative colitis]. Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology, 2003, Issue:1 Topics: Adult; Colitis, Ulcerative; Female; Humans; Male; Mesalamine; Recurrence; Sulfasalazine; Treatment O	2003
Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study. Alimentary pharmacology & therapeutics, 2004, Feb-15, Volume: 19, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Cohort Studies; Colitis, Ulcerativ	2004
Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis. Scandinavian journal of gastroenterology, 2004, Volume: 39, Issue:2 Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Colitis, Ulc	2004
Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. International journal of molecular medicine, 2004, Volume: 13, Issue:5 Topics: Adult; Colitis, Ulcerative; Dietary Fiber; Female; Germination; Hordeum; Humans; Male; Mesalamine; P	2004
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut, 2004, Volume: 53, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double	2004
A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Alimentary pharmacology & therapeutics, 2005, Jan-15, Volume: 21, Issue:2 Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind	2005
Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2005, Volume: 37, Issue:2 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colit	2005
The suspension of an announced trial on relapse prevention in Crohn's ileitis with a 5-ASA formulation in microgranular form. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2005, Volume: 37, Issue:2 Topics: Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease; Dose-Response Relationship, Drug; Double-Bli	2005
Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Alimentary pharmacology & therapeutics, 2005, May-01, Volume: 21, Issue:9 Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc	2005
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. The American journal of gastroenterology, 2005, Volume: 100, Issue:11 Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc	2005
Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. Digestive diseases and sciences, 2007, Volume: 52, Issue:3 Topics: Aged; Aged, 80 and over; Diverticulum, Colon; Female; Humans; Male; Mesalamine; Middle Aged; Prospec	2007
Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. International journal of colorectal disease, 2007, Volume: 22, Issue:9 Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Bifidobacterium; Diverticulitis	2007
Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflammatory bowel diseases, 2007, Volume: 13, Issue:9 Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Admi	2007
Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial. Journal of gastroenterology and hepatology, 2007, Volume: 22, Issue:6 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Biopsy; Chi-Square D	2007
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut, 2008, Volume: 57, Issue:7 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Colitis, Ulcerative; Dela	2008
Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid. British medical journal (Clinical research ed.), 1982, Oct-09, Volume: 285, Issue:6347 Topics: Acrylic Resins; Administration, Oral; Adult; Aminosalicylic Acids; Clinical Trials as Topic; Colitis	1982
Remaining small bowel endoscopic lesions at surgery have no influence on early anastomotic recurrences in Crohn's disease. The American journal of gastroenterology, 1995, Volume: 90, Issue:11 Topics: Adult; Aminosalicylic Acids; Anastomosis, Surgical; Anti-Inflammatory Agents, Non-Steroidal; Colecto	1995
Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology, 1995, Volume: 109, Issue:2 Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; Con	1995
A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission. Journal of clinical gastroenterology, 1995, Volume: 20, Issue:3 Topics: Adolescent; Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease; Dou	1995
Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology, 1995, Volume: 108, Issue:2 Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease; Double-Blind Me	1995
5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis. The Italian journal of gastroenterology, 1994, Volume: 26, Issue:3 Topics: Administration, Oral; Adult; Aminosalicylic Acids; Colitis, Ulcerative; Drug Administration Schedule	1994
Oral 4-aminosalicylic acid versus 5-aminosalicylic acid slow release tablets. Double blind, controlled pilot study in the maintenance treatment of Crohn's ileocolitis. Gut, 1994, Volume: 35, Issue:8 Topics: Administration, Oral; Aminosalicylic Acid; Aminosalicylic Acids; Crohn Disease; Delayed-Action Prepa	1994
Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Alimentary pharmacology & therapeutics, 1994, Volume: 8, Issue:1 Topics: Administration, Oral; Adolescent; Adult; Aminosalicylic Acids; Crohn Disease; Female; Humans; Male;	1994
Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. Diseases of the colon and rectum, 1994, Volume: 37, Issue:1 Topics: Administration, Oral; Administration, Rectal; Adolescent; Adult; Aged; Aminosalicylic Acids; Colitis	1994
IBD: which 5-ASA drug works where? Journal of pediatric gastroenterology and nutrition, 1993, Volume: 16, Issue:4 Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Humans; Mesalamine; Recurrence	1993
Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis. A multicenter comparative trial with 5-ASA enema. Digestive diseases and sciences, 1993, Volume: 38, Issue:10 Topics: Administration, Rectal; Adult; Aminosalicylic Acids; Colitis, Ulcerative; Enema; Female; Humans; Mal	1993
[5-Aminosalicylic acid in the prevention of recurrences of Crohn's disease]. Deutsche medizinische Wochenschrift (1946), 1995, Dec-15, Volume: 120, Issue:50 Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Chi-Square Distribution; Crohn	1995
Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study. Journal of clinical gastroenterology, 1995, Volume: 21, Issue:4 Topics: Acrylic Resins; Adult; Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non	1995
Prognostic factors for postoperative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC) Diseases of the colon and rectum, 1996, Volume: 39, Issue:3 Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Combined Modality Therapy; Cro	1996
Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Gastroenterology, 1996, Volume: 110, Issue:3 Topics: Adolescent; Adult; Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Ste	1996
Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). European journal of gastroenterology & hepatology, 1996, Volume: 8, Issue:3 Topics: Administration, Oral; Adolescent; Adult; Aged; Aminosalicylic Acids; Anastomosis, Surgical; Anti-Inf	1996
Pilot trial of nicotine patches as an alternative to corticosteroids in ulcerative colitis. Journal of gastroenterology, 1996, Volume: 31, Issue:4 Topics: Administration, Cutaneous; Adult; Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory	1996
A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology, 1997, Volume: 112, Issue:4 Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease; Double-Blind Me	1997
Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. The American journal of gastroenterology, 1997, Volume: 92, Issue:7 Topics: Administration, Oral; Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis,	1997
Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. The American journal of gastroenterology, 1997, Volume: 92, Issue:12 Topics: Abdominal Pain; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti-Inflamm	1997
Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study. Gut, 1998, Volume: 42, Issue:2 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-Action Preparations; Do	1998
Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group. The American journal of gastroenterology, 1998, Volume: 93, Issue:5 Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug;	1998
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet (London, England), 1999, Aug-21, Volume: 354, Issue:9179 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Escherichi	1999
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet (London, England), 1999, Aug-21, Volume: 354, Issue:9179 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Escherichi	1999
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet (London, England), 1999, Aug-21, Volume: 354, Issue:9179 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Escherichi	1999
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet (London, England), 1999, Aug-21, Volume: 354, Issue:9179 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Escherichi	1999
Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:8 Topics: Adult; Aged; Bifidobacterium; Colitis, Ulcerative; Feces; Female; Humans; Hydrogen-Ion Concentration	1999
Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology, 2000, Volume: 118, Issue:2 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease; Double-Blind Method; Europe; Fe	2000
[Probiotics for prevention of ulcerative colitis recurrence: alternative medicine added to standard treatment?]. Zeitschrift fur Gastroenterologie, 2000, Volume: 38, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcera	2000
Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. The American journal of gastroenterology, 2000, Volume: 95, Issue:7 Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Fema	2000
Saccharomyces boulardii in maintenance treatment of Crohn's disease. Digestive diseases and sciences, 2000, Volume: 45, Issue:7 Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease; Female; Humans; Male; Mesalamine; Mid	2000
Allopurinol in addition to 5-aminosalicylic acid based drugs for the maintenance treatment of ulcerative colitis. Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:9 Topics: Adult; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Colitis, Ulcerat	2000
Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial. Lancet (London, England), 2001, Sep-22, Volume: 358, Issue:9286 Topics: Administration, Topical; Adolescent; Adult; Aged; Ambulatory Care; Anti-Inflammatory Agents; Anti-In	2001
Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet (London, England), 1992, May-23, Volume: 339, Issue:8804 Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Female; Humans; Life Tables; Mal	1992
Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. Digestive diseases and sciences, 1992, Volume: 37, Issue:1 Topics: Administration, Oral; Aminosalicylic Acids; C-Reactive Protein; Crohn Disease; Humans; Mesalamine; O	1992
Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis. Diseases of the colon and rectum, 1990, Volume: 33, Issue:5 Topics: Administration, Oral; Adult; Aminosalicylic Acids; Colitis, Ulcerative; Double-Blind Method; Enema;	1990
Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group. Alimentary pharmacology & therapeutics, 1990, Volume: 4, Issue:1 Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Crohn Disease; Double-Blind Method; Female; Humans; M	1990
[5-aminosalicylic acid in the long-term treatment of ulcerative colitis]. Zeitschrift fur Gastroenterologie, 1989, Volume: 27, Issue:4 Topics: Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Double-Blind Method; Female; Hu	1989
[Prevention of recurrence of chronic inflammatory bowel diseases]. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin, 1989, Volume: 95 Topics: Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Humans; Immunosu	1989
Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group. Alimentary pharmacology & therapeutics, 1989, Volume: 3, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Double-Bli	1989
Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine. The American journal of gastroenterology, 1988, Volume: 83, Issue:1 Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Clinical Tri	1988
Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut, 1988, Volume: 29, Issue:5 Topics: Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Delayed-Action Pre	1988
Colonic prostaglandin E2 levels and olsalazine metabolism in relapsing ulcerative colitis: implications for controlled trials in the long term. Scandinavian journal of gastroenterology. Supplement, 1988, Volume: 148 Topics: Adult; Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Colon; Dinoprostone; Fem	1988

mesalamine and Recrudescence